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CHAPTER I: 
Introduction 
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BREAST CANCER 
Carcinogenesis occurs due to a combination of genetic aberrations.  For example, 
children who have inherited a loss of function mutation in the retinoblastoma gene (RB1) are 
predisposed to developing retinoblastoma earlier than children who have accumulated 
somatic RB1 mutations1.  This finding was the basis for the Knudson two-hit hypothesis of 
tumorigenesis, which states that a loss of heterozygosity of a tumor suppressor gene 
predisposes these individuals to developing certain kinds of cancer.  This hypothesis is 
widely accepted and is applicable many childhood and adult malignancies, including breast 
cancer2.  In the year 2010, it is estimated that of the 1,529,560 newly diagnosed cancer cases 
in the United States, 209,060 (13.66%) of these cases will be breast cancers.  These numbers 
translate into roughly 28% of women and 0.25% of men that are newly diagnosed with 
cancer3.  Furthermore, 19.23% of female and 19.79% of male breast cancer patients are 
estimated to succumb to this disease3.  Phenotypically, breast cancer is a genetically complex 
and heterogeneous disease and is therefore categorized according to the expression of the 
human epidermal growth factor receptor-2 (Her2/neu), estrogen receptor (ER), and 
progesterone receptor (PR).  Breast cancers can be further stratified based on their gene 
expression profiles4.  Treatment options for breast cancer patients include surgery, radiation 
therapy, chemotherapy, biopharmaceuticals, and hormone therapy5.  In recent years, a 
substantial body of literature has accumulated suggesting that the tumor microenvironment, a 
combination of stromal cells, proteases, cytokines, and immune effector cells, also 
contributes to malignancy6. 
Proteases are indispensable for successful solid tumor growth and are abundant in the 
tumor microenvironment.  Many of these enzymes degrade the extracellular matrix, which is 
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required for angiogenesis, local invasion, and distant metastasis7.  Furthermore, extracellular 
matrix proteolysis increases tumor cell proliferation by liberating sequestered growth 
factors8.  In this introductory chapter, I present an overview the coagulation protease cascade, 
the protease-activated receptor family, and the fibrinolytic system.  In each chapter of this 
dissertation, I describe how these systems work in concert to promote tumor progression. 
 
TISSUE FACTOR 
Tissue factor (TF), also known as coagulation factor III (FIII), or cluster of 
differentiation 142 (CD142), is a 47kD transmembrane glycoprotein that is the cellular 
receptor for FVII/FVIIa9.  The TF/FVIIa complex triggers the extrinsic coagulation cascade, 
otherwise known as the TF pathway (Figure 1.1).  Briefly, the TF-FVIIa complex activates 
FX to FXa, which, in the presence of FVa, calcium, and phospholipids, forms the 
prothrombinase complex.  The prothrombinase complex converts prothrombin to thrombin, 
which then cleaves fibrinogen to fibrin and activates platelets. TF-FVIIa also activates FIX to 
FIXa.  The end result of this cascade is the generation of a clot composed of fibrin and 
platelets.   
TF is overexpressed in a variety of cancers10-12.  TF contributes to tumor angiogenesis 
as inhibition of TF reduces tumor vascularity in vivo12-14.  Additionally, deletion of the TF 
cytoplasmic domain delays mammary tumorigenesis in vivo15. Despite these findings, the 
coagulation proteases generated as a result of the TF-FVIIa complex have a more established 
role in tumor progression via their ability to activate protease-activated receptors (PARs). 
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Figure 1.1: The extrinsic coagulation cascade.  Tissue factor (TF) binds FVIIa on the cell surface, which then 
converts FX to FXa.  The prothrombinase complex (FXa+FVa+Ca2++phospholipids) cleaves prothrombin to 
thrombin.  Thrombin converts fibrinogen to fibrin in addition to activating platelets.  Platelets and fibrin form a 
clot.  TF-FVIIa also activates FIX to FIXa, which converts FX to FXa (not depicted).  Blue represents a 
transmembrane receptor and red signifies an active protease 
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PROTEASE-ACTIVATED RECEPTORS 
PARs are members of the G protein-coupled receptor (GPCR) family of which there 
are four16.  PAR-1 and PAR-2 are expressed on a variety of cell types.  Human endothelial 
cells express PAR-1, PAR-2, and PAR-3 whereas mouse endothelial cells express PAR-1, 
PAR-2, and PAR-417,18.  Human platelets express PAR-1 and PAR-4 while mouse platelets 
express PAR-3 and PAR-4.  PARs are unique in that their ligand is attached to the receptor 
itself.  Cleavage of the N-terminus of the receptor reveals this tethered ligand that then binds 
to the activation loop of the receptor to activate intracellular signaling pathways17,19 (Figure 
1.2).  PARs are activated by a variety of proteases, including coagulation proteases (Table 
1.1).  In particular, FVIIa and FXa activate PAR-2 while FXa, and thrombin activate PAR-
120.   
Both PAR-1 and PAR-2 are overexpressed in breast cancer patient samples21,22. 
Activation of PAR-1 and/or PAR-2 confers an advantage to tumor cells in vitro and in vivo.  
For example, inhibition of PAR-1 decreased the survival, migration, and metastasis of breast 
tumor cells23,24. In similar fashion, PAR-2 activation increased breast cancer cell migration, 
invasion, and expression of vascular endothelial growth factor in vitro, and inhibition of 
PAR-2 decreased tumor angiogenesis in vivo25-28. 
 
FIBRINOLYSIS 
Fibrinolysis, the proteolytic dissolution of fibrin clots, is controlled by the 
plasminogen activator system.  The key components of this system includes the serine 
proteases tissue plasminogen activator (tPA) and urokinase plasminogen activator (uPA), the 
urokinase plasminogen activator receptor (uPAR), and plasminogen.  In short, tPA released  
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Figure 1.2: Mechanism of proteolytic activation of PAR-1 and PAR-2.  A protease (red) cleaves the N-
terminus of the receptor proximal to the tethered ligand sequence (black box).  The new N-terminus 
interacts with the activation loop of the receptor to enable downstream signaling. 
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Table 1.1: Proteolytic PAR agonists 
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locally from endothelial cells and the cell surface bound uPA/uPAR complex efficiently 
convert plasminogen to the active serine protease plasmin which then degrades fibrin29.  The 
serine protease inhibitor (SERPIN), plasminogen activator inhibitor-1 (PAI-1), 
negativelyregulates fibrinolysis by binding to the active sites of tPA and uPA, thus inhibiting 
their proteolytic function.  Additionally, PAI-2 also inhibits tPA and uPA.  However, this 
SERPIN is present at extremely low levels in plasma29. 
uPA is  overexpressed in breast cancers and these elevated levels correlate with 
decreased relapse free survival and decreased overall survival rates in patients with invasive 
breast cancer30,31.  In vitro, uPA induces proliferation and invasion of breast cancer cells32,33.  
Additionally, overexpression of uPA increases breast cancer metastasis whereas reducing 
uPA decreases metastasis34-36.  Furthermore, in HER2+ breast cancer patient samples, 
elevated uPA levels correlate with increased metastasis37.  Moreover, inhibition of uPA 
and/or uPAR impaired endothelial cell tube formation and increased apoptosis of breast 
cancer cells in vitro38.  uPA bound to uPAR also provides localized proteolysis via cell 
surface plasmin generation.  In fact, plasmin activates matrix metalloproteinases (MMPs), 
which, in addition to plasmin itself, degrade the extracellular matrix, favoring cell 
invasion39,40. 
Although PAI-1 inhibits uPA function, paradoxically, PAI-1 also promotes 
malignancy (Figure 1.3).  For example, elevated PAI-1 levels in breast cancer patients are 
correlated with poor patient outcome30,31.  Moreover, elevations of PAI-1 correlate with 
increased metastasis in breast cancer patients41.  Similar to uPA, PAI-1 contributes to tumor 
angiogenesis and metastasis in vivo42,43.  Increased PAI-1 levels correlated with an increased  
 9 
Figure 1.3: uPA and its inhibitor, PAI-1, promote tumor progression.  Cell surface uPA has roles in 
tumor angiogenesis and tumor growth.  uPA converts plasminogen to plasmin thereby creating a zone of 
localized proteolysis (top).  Plasmin activity favors tumor cell invasion via matrix degradation and 
activation of MMPs.  PAI-1 inhibits uPA function, but in doing so promotes tumor angiogenesis and 
metastasis (bottom).  
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degree of vascular remodeling in clinical breast tumor samples44.  Additionally, inhibition of 
PAI-1 decreased in vitro migration of breast cancer cells45.  
Chapter 2 is a review the role of TF in cancer, focusing on the cellular distribution of 
TF and how this is relevant to tumor progression.  More specifically, I discuss TF expression 
in cancer cells and in non-malignant host cells, the contribution of TF-dependent PAR 
signaling and how this promotes tumor angiogenesis, tumor growth, and tumor metastasis.  
This review, “Tissue Factor Expression by Malignant Cells Contributes to Tumor 
Progression”, was recently published in the Journal of Coagulation Disorders. 
Chapter 3, entitled “Protease-Activated Receptors Mediate Cross-Talk Between 
Coagulation and Fibrinolysis”, was recently published as an original research article in 
Blood.  This body of work demonstrates that uPA is induced in response to the coagulation 
proteases FXa and thrombin via PAR-1 in 4T1 metastatic mouse breast cancer cells.  
Furthermore, I discovered that there are intracellular stores of uPA associated with the Golgi 
apparatus and that these stores are rapidly released upon PAR-1 activation.  Additionally, a 
novel PAR-dependent PAI-1 regulatory mechanism was revealed.  In short, transactivation of 
PAR-2 by thrombin-activated PAR-1 resulted in PAI-1 mRNA and protein expression. 
In Chapter 4, I further explore the PAI-1 regulatory mechanism discovered in Chapter 
3.  I found that activation of the PAR-1/PAR-2 complex activated the p42/p44 mitogen 
activated protein kinase (MAPK) signaling cascade and induced the phosphorylation of ets-
like gene 1 (ELK1), which increases the expression of the transcription factor early growth 
response-1 (EGR1), a known positive regulator of PAI-1 gene expression.  Furthermore, the 
p42/p44 MAPK pathway was necessary for PAI-1 protein expression.  Interestingly, I also 
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discovered that FXa induced p42/p44 MAPK intracellular signaling but did not result in 
increased EGR1 mRNA or protein expression.  
Chapter 5 is the discussion of the entirety of the experimental data presented in this 
dissertation.  Here, I present a model that illustrates how this data adds to the existing 
literature regarding breast cancer invasion and tumor angiogenesis.  Additionally, I address 
the limitations of my work and provide experimental suggestions to further continue the 
investigation of how PAR-1 and PAR-2 contribute to breast tumor progression.    
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ABSTRACT 
Tissue factor (TF) is a transmembrane protein that binds its ligand factor VII/VIIa 
(FVII/FVIIa) and initiates the coagulation protease cascade.  TF is essential for hemostasis. 
In addition, TF has been implicated in several pathological processes, including venous 
thromboembolism, sepsis, inflammation, and cancer.  Aside from their primary roles in 
coagulation, FVIIa and the downstream proteases FXa and FIIa (thrombin) can also cleave 
and activate protease-activated receptors (PARs) on cells to induce intracellular signaling. In 
this review, we will summarize the proposed mechanisms by which TF contributes to tumor 
progression.  Specifically, we will focus on how TF expression by cancer cells and host cells 
promotes malignancy by increasing angiogenesis, tumor growth, and metastasis.   
 
INTRODUCTION 
There has been a longstanding association between malignancy and coagulation.  This 
dates back to initial reports of increased hypercoaguability in cancer patients described by 
Armand Trousseau in the mid-19th century1.  Today, cancer associated thrombosis is a 
clinically relevant issue.  In a population-based case-control study, approximately 20% of all 
patients diagnosed with venous thromboembolism (VTE) were also diagnosed with a 
malignancy2.  In a large cohort study, Blom and colleagues reported that the risk of VTE in 
cancer patients is over 10 times greater than that of the cancer-free population3.  This risk 
was further increased in patients with distant metastasis or receiving chemotherapy.  An 
independent study reported that cancer patients had a 4-fold greater VTE risk in comparison 
to those without cancer4.  Tissue factor (TF) is a member of the class 2 cytokine receptor 
family and serves as the transmembrane receptor for coagulation factor VII (FVII)5.  
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Activated FVII (FVIIa) bound to TF initiates the coagulation protease cascade, which 
includes the proteases FXa, FVIIa, and FIIa (thrombin), resulting in the formation of a fibrin 
clot6,7. 
There is a significant correlation between the incidence of VTE and TF levels in 
cancer patients8-12.  Furthermore, TF is expressed in a variety of malignancies, most notably 
in breast, brain, colorectal, lung, renal cell, ovarian, prostate, hepatocellular, and pancreatic 
cancers13.  According to the American Cancer Society, it is estimated that, when combined, 
these cancers will account for roughly 59% of all newly diagnosed cases in the United States 
in 201014. Furthermore, elevated levels of TF correlate with a reduced disease-free survival 
and overall survival rate15-17.  This may reflect the fact that increased TF levels coincide with 
tumor aggressiveness both in vitro and in vivo.  Recent studies have attempted to understand  
the mechanisms linking TF expression and tumor progression.  This review will focus on TF-
dependent activation of coagulation on the tumor cell surface and how this contributes to 
tumor progression via signaling through protease-activated receptors (PARs).   
 
TF EXPRESSION BY CANCER CELLS 
Oncogene activation and loss of tumor suppressor genes, two genetic insults required 
for carcinogenesis, increase  TF expression in transformed cells.  For instance, oncogenic 
activation of v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (K-ras), epidermal 
growth factor (EGFR), mutant EGFR (EGFRvIII), human epidermal growth factor receptor-2 
(HER-2), as well as loss of the tumor suppressor genes phosphatase and tensin homolog 
(PTEN) and p53, all increase TF expression in a variety of cancer cells18-21.  A recent report 
indicated that ectopic expression of EGFRvIII in human glioblastoma cells induced the 
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expression of TF, PAR-1, PAR-2, and FVII22.  This equips these tumor cells with the 
necessary components for TF-dependent PAR signaling.  Furthermore, pharmacological 
inhibition of the oncoproteins EGFR and HER-2 diminished TF expression in human 
squamous cell carcinoma and human breast carcinoma cell lines, respectively18. 
The tumor microenvironment also modulates TF expression in tumor cells.  There is 
an abundance of inflammatory cytokines and chemokines present within the tumor stroma, 
many of which increase the activation of the nuclear factor-kappa B (NF-κB) signal 
transduction pathway23,24. Interestingly, tumor cells have high levels of NF-κB transcription 
factor activity25-28, which may contribute to the high TF expression in tumor cells as previous 
studies have shown that inducible TF gene transcription in monocytes and endothelial cells is 
controlled, in large part, by NF-κB29-31.   
Interestingly, statins have been shown to attenuate NF-κB signaling32,33.   In vitro, 
simvastatin inhibited nuclear translocation of NF-κB and decreased TF mRNA expression 
and TF-dependent signaling in tumor cells in vitro34.  TF has a 100 amino acid domain that is 
structurally related to cytokine receptors leading to its classification as a member of the class 
2 cytokine receptor family5.  In addition to NF-κB, the TF promoter is also regulated by the 
transcription factor early growth response-1 (EGR1)35.  Brat and colleagues have shown that 
hypoxia positively regulates tumor cell TF expression and activity by inducing the expression 
EGR136,37. 
TF expression is not restricted to the cell surface as tumors are capable of shedding 
TF-positive microvesicles, also called microparticles8,38.  In vitro, ovarian cancer cells have 
been shown to release TF-positive microparticles39.  Our laboratory has demonstrated that 
tumor cells are a major source of TF-positive microparticles in vivo in a human pancreatic 
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cancer xenograft mouse model (Wang and Mackman, unpublished data).  Moreover, murine 
tumor cells release TF-positive microparticles into the circulation40.  In addition, an 
alternatively spliced form of TF (asTF) lacking both the transmembrane and cytoplasmic 
domains has been identified41.  asTF is released from cultured pancreatic tumor cells and has 
been reported to promote the growth and angiogenesis of pancreatic tumors in vivo42,43.  
Additional TF splice variants have also been identified in tumor cells, although their 
contribution to tumor progression has yet to be established44. We, and others, have also 
shown that TF-positive microparticles are increased in cancer patients9-11,45.  It is evident that 
the aberrant expression of cancer cell TF is regulated at multiple levels, reflecting the 
complexity and diversity of neoplastic cells. 
 
TF EXPRESSION BY NON-MALIGNANT HOST CELLS 
Tumors are often referred to as “wounds that do not heal” highlighting the potent 
inflammatory response and subsequent tissue remodeling that is inherent in both of these 
processes46.  As discussed earlier, tumors are a major source of inflammatory mediators, 
including tumor necrosis factor-alpha (TNF-α), interleukin-1 (IL-1), and IL-623,24.  Both 
TNF-α and IL-1 induce TF expression in cultured endothelial cells29,47,48. Additionally, 
activation of endothelial cell PAR-1 has been shown to induce TF expression in these cells49.  
An additional component of the heterogeneous cell population that comprises solid tumors 
are fibroblasts50,51.  Fibroblasts express high levels of TF and this expression can be further 
increased by transforming growth factor-beta (TGF-β), which is present within the tumor 
stroma52.  Additionally, activated macrophages and neutrophils, both of which express TF, 
comprise a significant portion of the solid tumor mass53-56. 
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Activated monocytes and macrophages are also a source of TF-positive 
microparticles 57,58.  These microparticles allow transfer of TF to a variety of cells.  A clinical 
case study on plasma from a patient with giant-cell lung carcinoma observed circulating TF-
positive microparticles bearing the monocyte marker CD1459.  A second study of colorectal 
cancer patients found that the circulating TF-positive microparticles in the patient plasma 
samples were positive for either CD14 or the leukocyte common antigen CD4560.  In addition 
to docking to tumor cells, it was demonstrated that monocyte-derived TF-positive 
microparticles fused with the membranes of endothelial cells and neutrophils, thereby 
conferring a procoagulant phenotype on these non-malignant host cells61,62. 
 
TF AND COAGULATION PROTEASES INCREASE TUMOR ANGIOGENESIS 
TF expression is essential for hemostasis and proper blood vessel development63. 
Additionally, localized activation of coagulation on endothelial cells may contribute to 
angiogenic signaling to repair damaged vessels64.  TF has also been implicated in tumor 
angiogenesis.  TF was localized to the vascular endothelium within tumors samples of 
patients with invasive breast cancers but not in samples from patients with benign fibrocystic 
disease65.  However, Luther et al. reported that TF is indiscriminately expressed in both 
benign and malignant mammary tissue growths66. Despite the controversy, recent 
publications do suggest that the expression of tumor cell TF is associated with tumor 
angiogenesis.  For example, overexpression of tumor cell TF increased tumor vascularization 
in vivo and increased vascular endothelial growth factor (VEGF) expression as well as 
decreased the expression of the anti-angiogenic molecule thrombospondin (TSP) in vitro67.  
Conversely, silencing TF in Meth-A sarcoma or colorectal cancer cells resulted in decreased 
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tumor angiogenesis, decreased VEGF expression, and increased TSP expression21,67.  
Additionally, an anti-TF antibody reduced tumor vascularity and VEGF expression in human 
squamous carcinoma cells in vivo20. In clinical prostate cancer samples, TF expression 
correlates with VEGF expression, further suggesting a role for TF in tumor angiogenesis68.  
PARs are members of the seven membrane-spanning G-protein coupled receptor 
family69.  These receptors are proteolytically activated by a variety of different proteases, 
including coagulation proteases70.  For instance, FVIIa and FXa cleave PAR-2 to induce 
intracellular signaling, while FXa and thrombin cleave PAR-1 (Figure 2.1)70,71.  Interestingly, 
PAR-1 and PAR-2 are upregulated in pancreatic cancer cells and are thought to be a part of 
the “angiogenic switch”72.  Treatment of the MDA-MB-231 human breast cancer cell line 
with FVIIa, FXa, or thrombin induced IL-8 expression in vitro73,74.  In a separate study, IL-8 
promoted endothelial cell survival, proliferation, and secretion of matrix remodeling 
proteases, all of which are required for angiogenesis75.  Together, this suggests that tumor-
derived IL-8 may function as a pro-angiogenic stimulus for endothelial cells.   
In certain tumors, host-derived TF also contributes to tumor angiogenesis as 
exemplified by the finding that TF expressing tumors grown in mice expressing low levels of 
TF have smaller blood vessels compared with controls76.  Fibroblasts have been shown to 
secrete VEGF in a TF-FVIIa-FXa and thrombin-dependent manner77.  As mentioned earlier 
treatment of tumor cells with coagulation proteases induced the expression of a variety of 
chemokines, thereby enhancing leukocyte recruitment into the tumor stroma.  Once recruited 
into the tumor stroma, tumor associated macrophages (TAMs) and tumor associated 
neutrophils (TANs) further enhance angiogenesis78-80.  In fact, a recent study has shown that 
a lack of PAR-2 and/or the lack of the cytoplasmic domain of TF resulted in a 
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Figure 2.1:  Tissue factor-dependent activation of PARs contributes to tumor progression.  TF 
expressed on the tumor cell surface activates the coagulation cascade once bound to factor VIIa (FVIIa).  
Intracellular signaling is induced when the TF-FVIIa complex or FXa cleave PAR-2.  Activation of PAR-1 
by FXa or thrombin will also induce signaling.  PAR activation results in the expression of genes that 
promote tumor growth, tumor angiogenesis, and tumor metastasis.   
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reduction of TAMs and decreased vascular density in a polyoma middle-T breast cancer 
model81. 
 
TF AND COAGULATION PROTEASES PROMOTE TUMOR GROWTH 
Experimental evidence reveals that TF influences tumor growth. One mechanism by 
which TF and coagulation proteases may contribute to tumor growth is via PAR-1 dependent 
inhibition of apoptosis.  Incubation of human breast tumor cells with either FVIIa and FX or 
FXa resulted in a significant decrease in apoptosis of serum-starved tumor cells82.  
Furthermore, TF-FVIIa and TF-FVIIa-FXa signaling also decreased apoptosis in baby 
hamster kidney (BHK) cells83.  
Overexpression of TF increased the growth of Meth-A sarcoma tumors in vivo 
whereas reduced TF expression was associated with decreased tumor growth67.  Likewise, 
reducing TF expression in colorectal cancer cells resulted in decreased tumor volume in 
vivo21.   Furthermore, inhibition of TF substantially delayed the initial onset of human 
epithelial carcinoma growth in vivo20. Conversely, overexpression of TF in a TF-deficient 
human pancreatic cell line dramatically increased the growth rate of the implanted tumors84.   
Inhibiting different steps in the coagulation pathway with anticoagulants has also 
been explored as a means of reducing tumor growth. In an attempt to determine which 
component of the TF pathway is responsible for the growth of certain tumors in vivo, TF-
FVIIa was inhibited with recombinant nematode anticoagulant protein c2 (rNAPc2) while 
FXa was inhibited with rNAP5, a nematode anticoagulant protein specific for FXa85.  
rNAPc2 reduced the growth of melanoma cells whereas rNAP5 did not, suggesting that the 
TF-FVIIa complex contributes to tumor growth of melanoma cells.  In a separate study, 
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rNAPc2 reduced the mitotic index, tumor weight, and tumor volume of colorectal cancer 
xenografts86.  Similarly, Ixolaris, a tick anticoagulant protein that inhibits the TF-FVIIa 
complex, reduced  the growth of glioblastoma xenografts87.   
Other tumors may utilize different mechanisms downstream of TF-FVIIa to confer a 
growth advantage.  For instance, thrombin was recently proposed to be a tumor growth 
factor88.  Indeed, one study revealed that thrombin stimulation induced cell cycle activation 
of prostate cancer cells89. However, thrombin inhibition appears to be tumor specific as 
hirudin inhibited B16 melanoma growth in vivo but not the growth of K1735 melanoma or 
colon cancer cells90.  
 
TF-DEPENDENT ACTIVATION OF COAGULATION PROMOTES TUMOR CELL 
INVASION AND METASTASIS  
The presence of TF initiates the local generation of coagulation proteases on the 
tumor cell surface91.  In vitro, FVIIa, FXa, and thrombin activate PARs on tumor cells to 
promote migration and invasion73,92-94.  Ectopic TF expression in a human pancreatic cancer 
cell line increased in vitro tumor cell invasion84.  In glioma cells, inhibition of TF decreased 
tumor cell migration and invasion in vitro95.  Mueller and Ruf demonstrated that TF 
expression in Chinese hamster ovary (CHO) cells enhances experimental hematogenous 
metastasis96.  The candidate mechanism by which TF-dependent PAR activation enhances 
tumor invasion is likely via increased extracellular matrix proteolysis.  Treatment of breast 
cancer cells with FVIIa, FXa, or thrombin increased the release of urokinase plasminogen 
activator (uPA) and plasminogen activator inhibitor-1 (PAI-1) from the cells in a PAR-
dependent manner74,97,98.  Both uPA and PAI-1 contribute to tumor cell invasion and 
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metastasis in vitro and in vivo99-101.  Thrombin-dependent signaling also promotes 
extracellular matrix degradation via expression of matrix metalloproteinases (MMPs).  
Thrombin increased in vitro invasion via the expression and release of MMP-9 and the 
expression of β1-integrin in osteosarcoma cells, as well as via increased MMP-2 and MMP-
13 expression in human chondrosarcoma cells102,103.  Furthermore, thrombin induced the 
expression of the protease cathepsin-D in murine breast cancer cells, which coincided with 
increased invasion104. 
Inhibition of TF with an anti-TF inhibitory antibody (5G9) or covalently inactivated 
FVIIa (FVIIai) reduced the number of experimental metastatic foci in the lungs of mice96.  
Likewise, inhibition of TF decreased melanoma metastases to the lung105.  Tissue factor 
pathway inhibitor (TFPI), the endogenous inhibitor of TF, also reduced the experimental 
metastasis of melanoma cells106.  Additionally, pharmacological inhibition of TF reduced 
metastasis in an in vivo model of colorectal cancer86.  The current hypothesis is that TF 
expression by tumor cells leads to fibrin coating of the cells that reduces natural killer cell 
anti-tumor activity and promotes tumor cell adhesion to the endothelium, thus promoting 
hematogenous metastasis107-109.  
TF-FVIIa-PAR2 signaling induced the expression of IL-8, granulocyte-macrophage 
colony stimulating factor, (GM-CSF), and macrophage colony stimulating factor (M-CSF) in 
a variety of breast cancer cell lines73,74.  These chemokines recruit leukocytes into the tumor 
stroma.  Once recruited, these leukocytes may become TAMs or TANs, thereby promoting 
tumor invasion and metastasis110-113.  In fact, the presence of thrombin within the tumor 
stroma may facilitate this process as thrombin stimulated macrophages adopted a TAM 
phenotype, resulting in increased invasion of ovarian cancer cells114. 
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CONCLUSION 
There is a substantial amount of data implicating TF, coagulation proteases, and 
PARs in tumor angiogenesis, growth, and metastasis.  Despite these advances, several 
questions still remain.  It is generally accepted that tumors are the major source of TF in 
malignancy.  However, at the present it is unclear how TF expression by non-malignant host 
cells within the tumor stroma contributes to tumor progression.  What is the functional 
relevance of TF-positive microparticles in tumor progression?   Can TF be used as a reliable 
biomarker for malignancy?  Overall, TF  is an attractive target for anti-caner therapy.  
Further studies are needed to determine which specific targets of the TF pathway are the 
most efficacious and whether the potential hemorrhagic complications of targeting TF or 
thrombin are worth the risk in comparison to targeting PARs. 
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ABSTRACT 
 The coagulation and fibrinolytic systems contribute to malignancy by increasing 
angiogenesis, tumor growth, tumor invasion, and tumor metastasis. Oncogenic 
transformation increases the expression of tissue factor (TF) that results in local generation of 
coagulation proteases and activation of protease-activated receptor (PAR)-1 and PAR-2. We 
compared the PAR-dependent expression of urokinase plasminogen activator (uPA) and 
plasminogen activator inhibitor (PAI)-1 in two murine mammary adencocarcinoma cell lines: 
metastatic 4T1 cells and non-metastatic 67NR cells. 4T1 cells expressed TF, PAR-1 and 
PAR-2 whereas 67NR cells expressed TF and PAR-1. We also silenced PAR-1 or PAR-2 
expression in the 4T1 cells. We discovered 2 distinct mechanisms for PAR-dependent 
expression of uPA and PAI-1. First, we found that factor Xa or thrombin activation of PAR-1 
led to a rapid release of stored intracellular uPA into the culture supernatant. Second, 
thrombin transactivation of a PAR-1/PAR-2 complex resulted in increases in PAI-1 mRNA 
and protein expression. Cells lacking PAR-2 failed to express PAI-1 in response to thrombin 
and factor Xa did not activate the PAR-1/PAR-2 complex. Our results reveal how PAR-1 and 
PAR-2 on tumor cells mediate cross-talk between coagulation and fibrinolysis. 
 
INTRODUCTION 
 Tissue factor (TF) is the cell surface receptor for coagulation factor VII/VIIa 
(FVII/VIIa). TF is expressed on various cell types and its expression is upregulated by 
oncogenic transformation, conferring a procoagulant phenotype to cancer cells1-4. Tumor cell 
TF locally activates the coagulation cascade when clotting factors in the blood enter the 
stroma from leaky tumor vasculature. Indeed, coagulation proteases, such as factor VIIa 
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(FVIIa), factor Xa (FXa), and thrombin, have been shown to contribute to tumor 
proliferation, migration, and angiogenesis5-8. 
 The mechanism by which coagulation proteases exert their tumor enhancing effects is, 
in part, via activation of protease-activated receptor (PAR)-1 and PAR-29-12. PARs belong to 
a family of G-protein coupled receptors that are proteolytically activated by a variety of 
proteases. FXa and thrombin activate PAR-1, whereas FVIIa and FXa activate PAR-29,13,14.  
In addition, PAR-1 can be activated by matrix metalloproteinase-1, plasmin, and activated 
protein C bound to endothelial protein C receptor (APC-EPCR)13,15-17. Trypsin, tryptase, 
kallikreins, and matriptase activate PAR-2 (for review, see Trejo18). Furthermore, PARs can 
transactivate one another. For instance, thrombin can bind to the N-terminus of PAR-3, 
which acts as a cofactor that allows the protease to activate PAR-4 and induce intracellular 
signaling in mouse platelets19.  In human platelets PAR-1 and PAR-4 both signal. In addition, 
PAR-1 forms a heterodimer with PAR-4 to initiate signaling in response to thrombin20.  
Furthermore, O’Brien and colleagues demonstrated, using pharmacological inhibitors of 
PAR-1 and a mutant PAR-1 incapable of signaling, that thrombin cleaved PAR-1 can 
transactivate PAR-2 in human endothelial cells and transfected COS-7 cells21. 
 Urokinase plasminogen activator (uPA) is a serine protease that converts plasminogen 
to plasmin. Plasminogen activator inhibitor (PAI)-1 is the endogenous inhibitor of uPA that 
forms a heterotrimeric complex with uPA and the uPA receptor (uPAR)22. Aside from their 
roles in regulating fibrinolysis, both uPA and PAI-1 promote metastasis22-25. Furthermore, 
uPA and PAI-1 are also involved in angiogenesis and endothelial cell migration26-28. 
Increased levels of uPA and PAI-1 are found in breast cancer patients, both correlating with 
poor prognosis and reduced survival29,30. Proteolytic activation of PAR-2 by FVIIa bound to 
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TF increases uPA, PAI-1, and uPAR mRNA expression in human breast cancer and 
pancreatic cancer cell lines31,32. PAR-1 and PAR-2 agonist peptides also increase both uPA 
and PAI-1 mRNA levels in the MDA-MD-231 human breast cancer cell line31. 
The aim of this study was to determine the role of PAR-1 and PAR-2 in the crosstalk 
between coagulation proteases and the regulation of plasmin generation in breast cancer 
cells. We used nonmetastatic (67NR) and metastatic (4T1) murine mammary 
adenocarcinoma cell lines because TF, coagulation proteases, uPA, and PAI-1 have been 
shown to contribute to metastasis. Here we describe 2 different mechanisms by which FXa 
and thrombin regulate uPA release and PAI-1 mRNA expression. 
 
MATERIALS AND METHODS 
Reagents. 
Recombinant mouse FVIIa (mFVIIa) was provided by Dr Lars Petersen (Novo 
Nordisk). Purified human factor X (FX), FXa, and α-thrombin were obtained from 
Haematologic Technologies Inc. Puromycin dihydrochloride was obtained from Mediatech. 
Brefeldin A (BFA) was purchased from BD Biosciences. Dimethyl sulfoxide, Triton X-100, 
DAPI (4,6-diamidino-2-phenylindole), and dithiothreitol were obtained from Sigma-Aldrich. 
4-β-phorbol-12-myristate 13-acetate (PMA) was purchased from Cell Signaling 
Technologies. Complete protease inhibitor cocktail tablets and phosphatase inhibitor cocktail 
were purchased from Roche. 
 
Cell culture. 
 67NR and 4T1 mouse mammary adenocarcinoma cell lines were obtained from Dr. 
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Fred Miller (Michigan Cancer Foundation). The 67NR and 4T1 cells were derived from the 
same spontaneously arising primary tumor and therefore represent the varied metastatic 
potential that exists in cells within a single tumor33. Importantly, the 4T1 cell line 
spontaneously metastasizes to the lymph nodes, lung, liver, bone, and brain and is therefore 
regarded as a clinically relevant breast tumor model that closely recapitulates human stage IV 
metastatic disease34. Conversely, the 67NR cell line is nonmetastatic. Cells were maintained 
in mimimum essential medium-alpha (Gibco), with 10% fetal bovine serum (Omega 
Scientific), and 1% penicillin/streptomycin (Sigma-Aldrich). Before treatment with 
coagulation factors or BFA, cells were grown to confluence in 12-well plates (Corning Inc.) 
and serum-starved overnight in serum-free media (SFM). The following coagulation 
proteases or zymogens were diluted in SFM and used to treat the cells: recombinant mFVIIa, 
human zymogen FX, mFVIIa and FX, human FXa, and human α-thrombin. PMA was 
diluted in SFM and incubated with the cells for 1 hour. BFA or dimethyl sulfoxide vehicle 
control were diluted in SFM and cells were pre-incubated for 3 hours before the addition of 
coagulation proteases or zymogen. 
 
Short hairpin RNA. 
 Lentiviral particles carrying plasmids encoding short hairpin RNA (shRNA) to either 
mouse PAR-1 or mouse PAR-2 were obtained from the University of North Carolina at 
Chapel Hill (UNC-CH) shRNA Core Facility. The GFPshRNA control plasmid (Addgene 
plasmid 12273) was obtained from Addgene, and packaged into lentiviral particles by the 
UNC-CH shRNA Core Facility35. Cells were transduced using Viraductin (Cell Biolabs) 
according to manufacturers protocol with an additional spin inoculation at 1,250 x g for 90 
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minutes at 22°C before placing the cells in the incubator. Twenty-four hours 
posttransduction, 12µg/mL of puromycin was added to the culture media to select stable cell 
populations containing the lentivirus. Entire populations of cells were selected rather than 
single cell clones to minimize selecting individual clones that have phenotypically drifted 
from the parental 4T1 cells because of the lentiviral transduction. Five and 6 separate cell 
populations were generated for both PAR-1 and PAR-2 silenced 4T1 cells, respectively. 
Knockdown efficiency was determined by real time polymerase chain reaction (PCR) 
analysis. The cell populations with the highest silencing efficiency were used for the 
experiments. 
 
Real time PCR. 
 RNA was isolated from cells using the RNeasy Plus kit (QIAGEN). mRNA was 
reverse transcribed using the First Strand cDNA Synthesis kit with Oligo-dT primers 
(Fermentas). Exon-spanning gene specific primers (Table 3.1) were synthesized by 
Integrated DNA Technologies. Real time PCR was performed on a Mastercycler Gradient 
(Eppendorf) using the Maxima SYBR Green qPCR Master Mix (Fermentas). Relative 
mRNA levels were quantified using the ΔΔCt method normalized to hypoxanthine-guanine 
phosphoribosyl transferase (HPRT)36. 
 
uPA and PAI-1 enzyme-linked immunosorbent assay. 
 Cells were grown in 12-well plates to form confluent monolayers. Cells were then 
starved overnight in SFM (Gibco). After starvation, new SFM containing coagulation factors 
were added to the wells. Conditioned media was collected, centrifuged at 5,000 x g for 5 
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Table 3.1: Real Time PCR Primers 
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minutes at 4°C to remove cellular debris, and frozen at -20°C. To obtain whole cell lysates, 
lysis buffer (10nM HEPES [4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid], 1.5mM 
MgCl2, 10mM KCl, 0.05% NP-40 [nonyl phenoxypolyethoxylethanol], pH 7.9) containing 
complete protease inhibitor cocktail was added to the cells. Cells were then scraped, 
sonicated, and centrifuged at 20,000 x g for 10 minutes at 4°C to pellet the cellular debris. 
The supernatant was then removed and stored at -20°C. uPA and PAI-1 enzyme-linked 
immunosorbent assays (ELISAs) were performed according to the manufacturer’s protocol 
(Molecular Innovations). 
 
uPA immunofluorescence. 
 Cells were grown on chamber slides (BD Biosciences), starved, fixed, and 
permeablized using BD Cytofix/Cytoperm (BD Biosciences). The cells were then incubated 
with fluorescein isothiocyanate (green) conjugated uPA antibody (Molecular Innovations) 
and Alexa Fluor-555 (red) conjugated Golgi marker GM130 antibody (BD Biosciences) for 1 
hour at 4°C in the dark. Nuclei were counterstained with DAPI (blue). Slides were washed 
then mounted with HyrdoMount mounting medium (National Diagnostics). 
 
Immunoblotting. 
 Cells were grown to confluence, starved overnight, and treated with either 125nM FXa, 
20nM thrombin, or 200nM PMA. Cells were washed with cold phosphate-buffered saline and 
lysed in lysis buffer (Cell Signaling Technologies) containing 1mM dithiothreitol and 
phosphatase inhibitor cocktail. Samples were then sonicated and cleared of debris by 
centrifugation at 20,000 x g for 10 minutes at 4°C. Protein concentration was determined by 
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Bio-Rad protein assay and 50µg of lysate was combined with Laemmeli sample buffer, 
boiled, and the proteins were separated on a Novex Tris-Glycine 4% to 12% gradient gel 
(Invitrogen). Protein was transferred to polyvinylidene fluoride (PVDF) membranes 
(Millipore) and probed with an antibody against phosphorylated PKCµ at a 1:250 dilution 
(Cell Signaling Technologies) and an IRDye 800CW conjugated secondary antibody 
(Rockland) at a 1:10,000 dilution. The membranes were stripped in Restore Stripping Buffer 
(Thermo Scientific), blocked, and incubated with an antibody against glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) at a 1:5,000 dilution (Santa Cruz Biotechnology) and an 
Alexa Fluor 680 conjugated secondary antibody (Invitrogen) at a 1:10,000 dilution. Blots 
were visualized and quantified using the Odyssey Infrared Imaging System (Licor). 
 
Statistical analysis. 
All statistical analyses were performed using GraphPad Prism 4 for Mac (GraphPad 
Software). All data are presented as means ± standard error of the mean (SEM). One-way 
analysis of variance with a Bonferroni posthoc analysis was performed when indicated. For 2 
group comparisons, a 2-tailed Student t test was used. P ≤ .05 was considered statistically 
significant. 
 
RESULTS 
PAR-1 and PAR-2 mediate crosstalk between coagulation and fibrinolysis. 
 Unstimulated 4T1 and 67NR cells expressed basal levels of TF, PAR-1, uPA, and PAI-
1 mRNAs. Importantly, 4T1 cells expressed PAR-2 whereas the 67NR cells lacked 
detectable PAR-2 mRNA by real time PCR analysis (Figure 3.1-A and 3.1-B). It was  
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Figure 3.1. Coagulation proteases increase uPA and PAI-1 expression in the culture supernatant of 
4T1 and 67NR breast cancer cell lines.  (A-B) Real-time PCR analysis of TF, PAR-1, PAR-2, uPA, and 
PAI-1 mRNA expression in 4T1 cells (A) and 67NR cells (B).  Cells were grown to confluence and 
starved overnight.  Results are shown as mean ± SEM of at least three independent experiments. (C-E) 
Serum starved confluent cell monolayers were incubated 24 hours with the following coagulation factors: 
mFVIIa (10nM), FX (130nM), mFVIIa (10nM) and FX (130nM), FXa (125nM), or thrombin (FIIa; 
20nM).  Levels of uPA in treated 4T1 cells (C) and 67NR cells (D) were determined by ELISA. The 
amount of PAI-1 released from the treated 4T1 (E) and 67NR (F) cell lines was measured by a PAI-1 
ELISA. Results are shown as mean ± SEM of at least five independent experiments. *P≤0.05 and 
**P≤0.001 (control versus protease treated).   
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 determined using a one-stage clotting assay that 4T1 cells exhibited approximately 3-fold 
higher levels of TF activity than 67NR cells (data not shown). 4T1 cells were used for 
mFVIIa, FXa, and thrombin dose-titration experiments. mFVIIa did not increase the levels of 
either uPA or PAI-1 in the culture supernatant at 24 hours (Supplemental Figure S3.1-A and 
S3.1-B). FXa produced a dose-dependent increase of uPA but not PAI-1 (Supplemental 
Figure S3.1-C and S3.1-D). Treatment of the cells with thrombin led to dose-dependent 
increases of both uPA and PAI-1 in the cell culture supernatant (Supplemental Figure 3.1-E 
and S3.1-F). 
 Stimulation of 4T1 and 67NR cells with either mFVIIa or zymogen FX alone did not 
increase uPA levels in the culture supernatant (Figure 3.1C and 3.1-D). However, incubation 
of the 4T1 cells with both mFVIIa and FX resulted in high levels of uPA, whereas 67NR 
cells exhibited a more modest increase in uPA in response to the combination of mFVIIa and 
FX (Figure 3.1C and 3.1-D). The level of uPA generated when cells were incubated with 
both mFVIIa and FX was similar to the level observed with FXa alone (Figure 3.1C and 3.1-
D), demonstrating that mFVIIa is enzymatically active. Similarly, thrombin increased uPA 
levels in the culture supernatant of both cell lines (Figure 3.1C and 3.1-D). Interestingly, 
thrombin was the only protease capable of increasing PAI-1 levels in the culture supernatant 
of 4T1 cells (Figure 3.1-E). Importantly, incubation of the 67NR cells with any of the 
proteases failed to increase PAI-1 levels in the cell culture supernatant at 24 hours (Figure 
3.1-F). Similar results were obtained by adding mFVIIa, FX, a combination of mFVIIa and 
FX, FXa, or thrombin to 2 additional cell lines: the PAN02 pancreatic cancer cell line and the 
168FARN breast cancer cell line (data not shown). 
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Absence of PAR-2 is associated with a loss of thrombin induced PAI-1 expression. 
 Our data demonstrated that cells lacking PAR-2 did not express PAI-1 in response to 
thrombin stimulation. Therefore, we hypothesized that PAR-2 is required for the induction of 
PAI-1. To test this hypothesis, we silenced PAR-2 expression in 4T1 cells to determine its 
role in uPA and PAI-1 expression. We also silenced PAR-1 expression in 4T1 cells. The 
different stably transduced shRNA cell populations are referred to as 4T1GFP, 4T1ΔPAR-1, and 
4T1ΔPAR-2. PAR-1 and PAR-2 mRNA levels were knocked down in the 4T1ΔPAR-1 and 
4T1ΔPAR-2 by 95% and 80%, respectively (Figure 3.2-A and 3.2-B). Silencing PAR-1 
attenuated the FXa or thrombin-dependent increase of uPA protein (Figure 3.2-C). In 
contrast, levels of uPA in the culture supernatant of 4T1ΔPAR-2 cells in response to FXa or 
thrombin did not significantly differ from those observed in the 4T1GFP control cells (Figure 
3.2-C). As expected, silencing PAR-1 diminished the thrombin-dependent increase of PAI-1. 
Importantly, silencing PAR-2 expression also drastically reduced PAI-1 induction in 
response to thrombin treatment (Figure 3.2-D), supporting our hypothesis that PAR-2 is 
required for inducible PAI-1 expression. 
 Furthermore, we used Gene Sifter Analysis Edition, Version 3.4 (Geospiza) to mine in 
vivo gene array data from laser capture microdissected cells from orthotopic 67NR and 4T1 
primary tumors. The original data were submitted to the Gene Submission Omnibus database 
by Lou et al (GSE 11259)37. We found that 4T1 cells expressed significantly more PAR-2 
(33.54-fold) and PAI-1 (9.56-fold) than 67NR cells in vivo. This suggests that the differential 
PAR-2 expression between the 67NR and 4T1 cells is not a consequence of in vitro culturing 
conditions and that PAR-2 may indeed be needed for inducible PAI-1 expression in vivo. 
Taken together, our data indicate that PAR-1 is required for FXa and thrombin mediated 
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Figure 3.2.  Silencing PAR-1 and PAR-2 in 4T1 cells.  (A-B) Real-time PCR analysis of PAR-1 (A) and 
PAR-2 (B) mRNA expression in 4T1ΔPAR-1 and 4T1ΔPAR-2 cells expressed as a percentage of the 4T1GFP 
control.  PAR-1 and PAR-2 levels were normalized to HPRT mRNA.  uPA protein (C) and PAI-1 protein 
(D) were measured by ELISA after 24 hour incubation with FXa (125nM) or thrombin (20nM). Results are 
shown as mean ± SEM of three independent experiments. *P≤0.05 and **P≤0.001  (4T1GFP versus 4T1ΔPAR-
1), ¶P≤0.05 and ¶¶P≤0.001 (4T1GFP versus 4T1ΔPAR-2), §P≤0.05 and §§P≤0.001 (4T1ΔPAR-1 versus 4T1ΔPAR-2). 
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increases in uPA whereas both PAR-1 and PAR-2 are required for thrombin-dependent 
increases in PAI-1. 
 
Transcriptional and posttranslational regulation of PAI-1 and uPA. 
 To understand the mechanism by which PAR activation regulates uPA and PAI-1, we 
examined the kinetics of uPA and PAI-1 mRNA and protein expression in 4T1 cells treated 
with FXa or thrombin. uPA mRNA levels remained unchanged in 4T1 cells stimulated with 
either FXa or thrombin (Figure 3.3-A). This is in stark contrast to uPA protein, which was 
rapidly increased in the culture supernatant in response to a 1-hour treatment with FXa or 
thrombin, respectively (Figure 3.3-B). Further increases in uPA were observed throughout 
the 24-hour period. We also observed uPA release in response to a 1-hour incubation with 
FXa or thrombin in the PAN02 and 168FARN cell lines (data not shown). 
 Incubation of 4T1 cells with FXa did not significantly increase PAI-1 mRNA or protein 
levels (Figure 3.3-C and 3.3-D). In contrast, thrombin treatment of 4T1 cells increased PAI-1 
mRNA levels, reaching a maximum induction of 2.2-fold before returning to baseline by 24 
hours (Figure 3.3-C). An accumulation of PAI-1 protein in the culture supernatant was 
observed starting at 6 hours in thrombin treated 4T1 cells (Figure 3.3-D). 
 
4T1 cells contain a store of intracellular uPA associated with the Golgi. 
 Analysis of uPA by direct immunofluorescence in SFM treated 4T1 cells under basal 
conditions revealed that the protease was stored in the perinuclear region of the cell (Figure 
3.4-A). This uPA staining colocalized with the Golgi marker GM130, suggesting that 
intracellular uPA was associated with this secretory organelle. After treating the 4T1 cells for 
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Figure 3.3.  Time-course of uPA and PAI-1 mRNA and protein expression in 4T1 cells 
stimulated with FXa or thrombin.  Levels of uPA mRNA (A) and protein (B) were determined by 
real-time PCR and ELISA, respectively.  PAI-1 mRNA (C) and protein (D) induction were also 
measured using real-time PCR and ELISA.  uPA and PAI-1 mRNA levels were normalized to HPRT 
mRNA.  Results are shown as mean ± SEM of at least three independent experiments. *P≤0.05 and 
**P≤0.001 (control versus FXa treated).  §P≤0.05  and §§P≤0.001 (control versus thrombin treated). 
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Figure 3.4.  Stimulation of 4T1 cells with FXa or thrombin induces uPA secretion. (A) Intracellular 
uPA staining.  Sub-confluent 4T1 cells were starved overnight then incubated with either SFM, FXa, or 
thrombin for 30 minutes.  The cells were then fixed and permeablized on glass chamber slides. Cells 
were incubated with both uPA-FITC (green) and GM130-Alexa Fluor555 (red) antibodies, then 
counter-stained with DAPI (blue).  Slides were viewed on an Olympus BX51WI fluorescence 
microscope fitted with an Olympus DP70 cooled digital color camera.  Total magnification is 400X 
(10X ocular; 40X objective).  DP Controller version 2.2.1.227 software was used for image acquisition.  
GraphicConverter X V5.4 was used to compile images.  (B-C) Serum starved 4T1 cells were incubated 
with FXa (125nM) or thrombin (20nM) for 1 hour.  Cellular (B) and culture supernatant (C) uPA 
expressed as percentage of total uPA in 4T1 cells.  Results are shown as mean ± SEM of three 
independent experiments. *P≤0.05 (control versus FXa treated) and §P≤0.05 (control versus thrombin 
treated).  (D) Cells were treated with BFA (10µg/mL) or vehicle control then stimulated with FXa 
(125nM) or thrombin (20nM) for 1 hr.  uPA was quantified in cell culture supernatant. **P≤0.05 
(control versus FXa treated) and §P≤0.05 (control versus thrombin treated).  (E) uPA levels in the 
culture supernatant of 4T1 cells treated with 100nM or 200nM PMA for 1 hour. *P≤0.05 and 
**P≤0.001 (control versus PMA treated).  Results are shown as mean ± SEM of three independent 
experiments. 
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30 minutes with either FXa or thrombin, we observed a marked decrease in the intensity of 
uPA staining (Figure 3.4-A). Next, we measured levels of uPA in whole cell lysates and 
culture supernatants of 4T1 cells with or without FXa or thrombin treatment. After a 1-hour 
incubation with FXa or thrombin, cellular uPA levels diminished whereas levels in the 
culture supernatant increased (Figure 3.4-B and 3.4-C). 
 Next, we used BFA to inhibit budding of newly formed secretory vesicles from the 
trans-Golgi network. FXa or thrombin mediated release of uPA was decreased by 
approximately 50% when cells were pre-treated with BFA (Figure 3.4-D). In addition, we 
directly activated the secretory pathway by incubating 4T1 cells with PMA. Exposure of 4T1 
cells to PMA for 1 hour induced uPA release in a dose-dependent manner (Figure 3.4-E). 
 
FXa and thrombin activate the secretory signaling pathway in 4T1 cells. 
Protein kinase C-µ (PKCµ) is an intracellular signaling protein involved in secretion 
from the Golgi. Importantly, we detected phosphorylated PKCµ in 4T1 cells treated with 
FXa, thrombin, or PMA for 5, 10, or 15 minutes (Figure 3.5-A), which suggests that PKCµ is 
involved in uPA release. Our previous results demonstrate that activation of PAR-1 results in 
the rapid release of uPA in 4T1 cells. Therefore, we hypothesized that cleavage of PAR-1 
induces PKCµ phosphorylation. 4T1GFP, 4T1ΔPAR-1, and 4T1ΔPAR-2 cells were treated with 
SFM, FXa, thrombin, or PMA for 5 minutes, and the cell lysates were used to detect 
phosphorylation of SFM, FXa, thrombin, or PMA for 5 minutes, and the cell lysates were 
used to detect phosphorylation of PKCµ. 4T1ΔPAR-1 cells exhibited significantly decreased 
levels of PKCµ. 4T1ΔPAR-1 cells exhibited significantly decreased levels of phosphorylated 
PKCµ when treated with either FXa or thrombin in comparison to the 4T1GFP  
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Figure 3.5.  Coagulation proteases activate the secretory pathway in the 4T1 cell line.  (A) 4T1 cells 
were treated for the indicated amount of time with SFM, FXa, thrombin, or 200nM PMA.  Blots were 
probed with antibodies for p-PKCµ and GAPDH.  Data shown is representative of three independent 
experiments.  (B) 4T1GFP, 4T1ΔPAR-1, and 4T1ΔPAR-2 cells were treated with SFM, FXa, thrombin, or PMA 
for 5 minutes. Blots were probed with antibodies for p-PKCµ and GAPDH.  Phosphorylated PKCµ was 
quantified by dividing the background-corrected p-PKCµ signal intensity by the background corrected 
GAPDH signal intensity.  The blot shown is representative of at least three independent experiments.  
Quantification results are shown as mean ± SEM of at least three independent experiments. *P≤0.05 
(4T1GFP versus 4T1ΔPAR-1) and  #P≤0.05 (4T1ΔPAR-1 versus 4T1ΔPAR-2).   
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and 4T1ΔPAR-2 (Figure 3.5-B), thereby supporting our hypothesis that cleavage of PAR-1 
activates the secretory pathway. 
 
DISCUSSION 
 Our results show that FXa or thrombin mediated activation of PAR-1 induces a rapid 
release of uPA in murine mammary adenocarcinoma cells (Figure 3.6). In contrast to 
previous reports using human cells lines, we did not find evidence for the induction of uPA 
mRNA expression in the murine tumor lines used in this study31,32,38. Cellular uPA 
colocalized with the Golgi. In addition, inhibiting secretion with BFA decreased uPA protein 
release. BFA collapses the trans-Golgi network, thereby preventing trafficking of immature 
and newly synthesized secretory vesicles39. The portion of uPA not inhibited by BFA 
treatment presumably represents uPA that is already within mature secretory vesicles. 
Furthermore, uPA was released by PMA activation of the secretory pathway. Activated 
PKCµ translocates to the Golgi apparatus where it is involved in vesicular trafficking from 
the trans-Golgi network to the plasma membrane40. Phosphorylation of the 2 activation loops 
of PKCµ resulting from FXa or thrombin treatment is indicative of activation of this 
secretory pathway. Taken together, these data demonstrate a novel mechanism of uPA 
regulation downstream of cellular activation by FXa or thrombin. 
Both PAR-1 and PAR-2 are required for PAI-1 mRNA and protein expression 
because silencing of either receptor in 4T1 cells abolished the increase of PAI-1 in the 
culture supernatant. This result is consistent with the absence of inducible PAI-1 expression 
in breast tumor lines lacking PAR-2, such as 67NR cells. This codependency suggests that 
PAR-1 and PAR-2 are complexed together and that cleaved PAR-1 transactivates PAR-2 to  
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induce PAI-1 expression. Interestingly, thrombin, but not FXa, activated the PAR-1/PAR-2 
complex. These data are consistent with the thrombin-dependent activation of a PAR-1/PAR-
2 complex previously described by O’Brien et al21. Thrombin activated PAR-1 and 
transactivated PAR-2 have been shown to use separate intracellular signaling pathways in an 
endothelial cell model of sepsis using pharmacological inhibitors and siRNA against PAR-1 
or PAR-241. This may explain the differential regulation of uPA secretion and PAI-1 mRNA 
expression by PAR-1 and a PAR-1/PAR-2 complex, respectively, in tumor cells. 
Our model suggests that there is differential signaling in tumor cells containing either 
PAR-1 alone or both PAR-1 and PAR-2 (Figure 3.6). In cells expressing only PAR-1, FXa or 
thrombin activate the receptor resulting in uPA secretion. Thrombin activates PAR-1 in a 
membrane-independent manner whereas FXa is anchored to the membrane. This membrane 
tethering may be achieved when FXa is complexed with TF-FVIIa or when FXa is bound to 
the membrane. In cells that express both PAR-1 and PAR-2, we found evidence of a PAR-
1/PAR-2 complex. In these cells, we propose that PAR-1, the more abundantly expressed 
receptor, can exist as a lone receptor or as part of the PAR-1/PAR-2 complex, whereas all of 
the PAR-2 is sequestered into the complex. Importantly, unlike PAR-1 alone, the PAR-
1/PAR-2 complex is activated by thrombin but not by FXa. This thrombin-dependent 
cleavage of PAR-1 transactivates PAR-2 resulting in increased PAI-1 expression. Previous 
studies have shown that receptors, such as TF and PARs, are often clustered together in 
specialized membrane microdomains, namely caveolae and lipid rafts, to enhance 
signaling42. Presumably, PAR-1 and the PAR-1/PAR-2 complex reside in different 
membrane domains explaining why only a trans-acting protease, such as thrombin, is capable 
of activating both sets of PARs on the cell surface. 
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We were unable to observe a TF-FVIIa-PAR-2 dependent regulation of either uPA or 
PAI-1 in the 4T1 cell line. In contrast, TF-FVIIa-PAR2 signaling has been described using 
the human breast cancer cell line MDA-MB-23131,43. Using Oncomine (Compendia 
Biosciences), we mined gene array data (GSE 2603) and found that the mRNA levels of TF 
and PAR-2 were significantly greater than that of PAR-1 in MDA-MB-231 tumor 
xenografts44. We found similar results by quantitative real-time PCR using cultured MDA-
MB-231 cells (data not shown). TF-FVIIa-PAR-2 signaling was also observed in baby 
hamster kidney cells transfected with TF and human endothelial cells transfected with TF 
and PAR-245. Taken together, this suggests that the levels of TF and PAR-2 expressed on the 
4T1 cells are not high enough to support for TF-FVIIa-PAR-2 signaling. 
PARs enable cells to detect, and therefore respond to proteases present in the local 
environment. Tumor metastasis and angiogenesis, whether lymphatic or hematogenous, 
requires a variety of matrix remodeling proteases, including matrix metalloproteinase-1 and 
plasmin46,47. These proteases, in addition to mast cell tryptase, and tissue kallikreins, are 
present within the breast tumor stroma and are known to activate PAR-1 or PAR-218,48,49. 
Recently, it has been demonstrated that oncogenes increase TF, PAR-1, and PAR-2 
expression2. We hypothesize that the local generation of FXa and thrombin on the surface of 
tumor cells, in addition to the aforementioned proteases present in the tumor stroma, may 
activate PAR-1 or PAR-2, leading to increased release/expression of uPA and PAI-1. Both 
uPA and PAI-1 have established roles in matrix degradation, tumor motility, and 
angiogenesis22. Our study explains how the coagulation system may use PAR-1 and PAR-2 
to promote malignancy via increased generation of plasmin. 
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Supplemental Figure S3.1: mFVIIa, FXa, and thrombin dose titration in 4T1 cells. Serum starved 
confluent cell monolayers were incubated with the indicated concentrations of FXa and thrombin for 24 hours.  
Levels of uPA in cell culture supernatant of 4T1 cells treated with mFVIIa (A), FXa (C), and thrombin (E) were 
determined by ELISA.  PAI-1 levels the in cell culture supernatant of 4T1 cells treated with mFVIIa (B), FXa 
(D), and thrombin (F) was measured by ELISA.  Results are shown as mean ± SEM of at least five independent 
experiments. *P≤0.05 and **P≤0.001 (control versus protease treated). 
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ABSTRACT 
Protease-activated receptor-1 (PAR-1) and PAR-2 are overexpressed in cancer cells 
and activation of these receptors contributes to malignancy.  We have recently shown that 
thrombin activates PAR-1, which induces transactivation of PAR-2, resulting in increased 
plasminogen activator inhibitor-1 (PAI-1) expression in 4T1 murine mammary 
adenocarcinoma cells.  We analyzed the signal transduction pathways that regulate thrombin-
induced PAI-1 expression.  Thrombin stimulation activates the ERK1/2-ELK1-EGR1 
pathway.  Furthermore, inhibition of p42/p44 MAPK signaling reduced PAI-1 expression.  
These results begin to delineate the mechanism by which thrombin activates a PAR-1/PAR-2 
complex to induce PAI-1 expression in the 4T1 murine breast cancer cell line. 
 
INTRODUCTION   
 The G-protein coupled receptor (GPCR) family encompasses a large number of 
seven-pass transmembrane receptors.  Included in this family is the sub-family of protease-
activated receptors (PARs)1.  As their name suggests, PARs are activated by a proteolytic 
cleavage in their extracellular N-terminus2,3.  There are four PARs, PAR-1, -2, -3, and -4.  Of 
interest, PAR-1 is activated by the coagulation proteases FXa and thrombin3,4.  Other PAR-1 
agonists include matrix metalloproteinase-1, plasmin, and activated protein C5-8.  PAR-2 is 
activated by coagulation proteases FVIIa and FXa, and by trypsin, tryptase, and kallikriens9-
12.  Additionally, thrombin-activated PAR-1 transactivates PAR-2 in both human and mouse 
cells13,14.  PAR-1 and PAR-2 activation has been reported to induce numerous intracellular 
signaling pathways, including the nuclear factor kappa B (NFκB) and p42/p44 mitogen 
activate protein kinase (MAPK) pathways15.  In human breast cancer cells, PAR-dependent 
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signaling induces the expression genes that favor tumor progression, such as plasminogen 
activator inhibitor-1 (PAI-1)16.  We recently demonstrated that PAI-1 is induced by PAR-
1/PAR-2 transactivation14. 
 PAI-1 is a serine protease inhibitor (SERPIN) that inhibits fibrinolysis by binding to 
the active sites of urokinase plasminogen activator (uPA) and tissue plasminogen activator 
(tPA)17,18.  PAI-1 is a pleiotropic molecule that functions in hemostasis, angiogenesis, and 
vessel wall repair19.  Additionally, PAI-1 is widely expressed in a variety of cell types and 
contributes to cancer pathology by enhancing tumor angiogenesis, survival, and invasion20,21.   
PAI-1 is positively regulated by numerous signaling pathways including the phosphoinositide 
3-kinase (PI3K), p42/p44 MAPK, p38 MAPK, NFκB, and beta catenin (β-catenin) pathways, 
amongst others22.  These pathways increase PAI-1 expression in a cell type dependent 
manner.  In human breast cancer cells, the transcription factor ets-like gene-1 (ELK1) 
directly increases PAI-1 transcription in a p42/p44 MAPK-dependent manner23.  
Furthermore, in a murine liver cancer model, PAI-1 expression is driven by oncogenic 
MET24.  Moreover, PAI-1 expression can be increased by soluble mediators, such as 
transforming growth factor beta (TGF-β), and by environmental conditions, such as hypoxia, 
both of which are stimuli in breast cancer25,26.  In this study, we examined select intracellular 
signaling pathways and transcription factors that could regulate thrombin-induced PAI-1 
expression in 4T1 murine mammary adenocarcinoma cells.  We conclude that thrombin-
induced PAI-1 expression is regulated by PAR-2-dependent activation of the ERK1/2-ELK1-
EGR1 pathway. 
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MATERIALS AND METHODS 
Reagents. 
Purified human activated coagulation factor X (FXa) and α-thrombin (FIIa) were 
obtained from Haematologic Technologies Inc.  Dimethyl sulfoxide (DMSO), dithiothreitol 
(DTT), penicillin/streptomycin, guanidine HCl, nonyl phenoxypolyethoxylethanol (NP-40), 
and tris(hydroxymethyl)aminomethane (Tris) were obtained from Sigma. 4-β-phorbol-12-
myristate 13-acetate (PMA) was purchased from Cell Signaling Technologies. 1,4-Diamino-
2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene (U0126) and the PAR-2 agonist peptide 
2f-LIGRLO-amide were purchased from Calbiochem.  Complete protease inhibitor cocktail 
tablets and phosphatase inhibitor cocktail were obtained from Roche. 
  
Cell culture.   
 4T1 cells were provided by Dr Fred Miller (Michigan Cancer Foundation).  4T1 cells 
were routinely cultured in minimal essential medium (MEM)-alpha (Gibco) supplemented 
with 10% fetal bovine serum (FBS; Omega Scientific), and 1% penicillin/streptomycin.  
Cells were grown to 100% confluence in 12-well tissue culture plates (Corning Inc.) then 
starved for 16 hours in serum-free media (SFM).  Following serum starvation, fresh SFM 
containing FXa (125nM) or thrombin (20nM) was added to the wells.  Complete culture 
media supplemented with 200nM PMA was used as a positive control (FBS+PMA).  For 
inhibitor studies, U0126 (10µM) or DMSO (volume/volume), the vehicle control, was added 
to the cells 1 hour prior to agonist treatment. 
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Immunoblotting.   
Following agonist treatment, cells were washed with ice-cold phosphate buffered 
saline and lysed in lysis buffer (Cell Signaling Technologies) supplemented with 1mM DTT 
and phosphatase inhibitor cocktail.  Cells were scraped and transferred into 1.5mL 
microcentrifuge tubes and sonicated on ice for 30 seconds.  The lysates were cleared of 
debris by centrifugation at 20,000 x g for 10 minutes at 4oC.  The Bio-Rad DC protein assay 
(Bio-Rad Laboratories) was used to determine the protein concentration in each sample.  
Protein lysates were combined with Laemmeli sample buffer and boiled at 100oC for 5 
minutes.  The reduced lysates were separated on a Novex Tris-Glycine 4%-12% gradient 
polyacrylimide gel (Invitrogen).  The proteins were transferred to Immobilon-FL PVDF 
membranes (Millipore). The membranes were probed with antibodies against phosphorylated 
extracellular signal-regulated kinase 1/2 (pERK1/2), total ERK1/2 (ERK1/2), phosphorylated 
ELK1 (pELK1), early growth response-1 (EGR1; Santa Cruz Biotechnology), or inhibitory 
kappa B alpha (IκBα; Cell Signaling Technologies).  ELK1 and EGR1 blots were stripped in 
stripping buffer (6M guanidine HCl, 0.2% NP-40, 20mM Tris, 10mM dithiothreitol, pH 7.5) 
then probed with antibodies against total ELK1 or glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH; Santa Cruz Biotechnology), respectively.  Alexa Fluor 680 and 
Alexa Fluor 800 conjugated secondary antibodies (Invitrogen) were used.  The membranes 
were scanned and bands quantified using the Odyssey Infrared Imaging System (Licor 
Biosciences). 
 
Real time PCR.  
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RNA was isolated from cells using the RNeasy Plus kit (Qiagen) following the 
manufacturer’s protocol. mRNA was reverse transcribed using the First Strand cDNA 
Synthesis kit with Oligo-dT primers (Fermentas).  EGR1 and hypoxanthine-guanine 
phosphoribosyltransferase (HPRT) primers were synthesized by Integrated DNA 
Technologies.  Primer sequences are as follows: EGR1 forward 5’-AAC AAC CCT ATG 
AGC ACC TGA CCA-3’; EGR1 reverse 5’-AGT CGT TTG GCT GGG ATA ACT CGT-3’; 
HPRT forward 5’-CTG GTG AAA AGG ACC TCT CG-3’; HPRT reverse 5’-TGA AGT 
ACT CAT TAT AGT CAA GGG CA-3’.  Real time PCR was performed on a Mastercycler 
Gradient (Eppendorf) using the Maxima SYBR Green qPCR Master Mix (Fermentas).  The 
ΔΔCt method was used to calculate the relative mRNA levels27.  EGR1 mRNA levels were 
normalized to the levels of HPRT mRNA.  
 
PAI-1 enzyme-linked immunosorbent assay (ELISA).  
 Following 24-hour agonist treatment, cell culture supernatants were collected and 
cleared of debris by centrifugation at 5,000 x g for 5 minutes at 4oC.  A murine total antigen 
PAI-1 ELISA was used to quantify PAI-1 levels in the cell culture supernatants (Molecular 
Innovations). 
 
Statistical analysis.   
 All statistical analyses were performed using GraphPad Prism 4 for Mac (GraphPad 
Software). All data are presented as means ± standard error of the mean (SEM).  Two-tailed 
student t tests were used to determine statistical significance.  Real time PCR data was 
analyzed using a two-way analysis of variance (ANOVA) with a Bonferroni post-hoc 
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analysis.  P values ≤ 0.05 were considered statistically significant. 
 
RESULTS 
FXa and thrombin activate the p42/p44 MAPK signaling pathway in 4T1 cells.   
 The agonist incubation time points were chosen based on unpublished preliminary 
data obtained using the human breast cancer cell line MDA-MB-231.  We found that FXa 
and thrombin activated the p42/p44 MAPK signaling pathway in 4T1 cells.  Western blot 
analysis revealed that FXa and thrombin both significantly increased the phosphorylation of 
ERK1/2 (Figure 4.1-A).  The p42/p44 MAPK pathway was further explored by examining 
downstream targets.  The transcription factor ELK1 is phosphorylated by pERK1/228.  
Stimulating 4T1 cells with FXa or thrombin for 5 minutes increased ELK1 phosphorylation 
(Figure 4.1-B).  The NFκB pathway was also analyzed.  4T1 cells stimulated with the 
positive control, FBS+PMA, induced IκBα degradation, indicating activation of the NFκB 
pathway.  However, neither FXa nor thrombin activated this signaling pathway in 4T1 cells 
(Figure 4.1-C). 
 
Thrombin, but not FXa, induces EGR1 mRNA and protein expression in 4T1 cells. 
Phosphorylated ELK1 (pELK1) has been shown to induce the expression of the transcription 
factor EGR129.  A time course experiment was performed to measure EGR1 mRNA levels by 
real time PCR.  In response to thrombin stimulation, EGR1 mRNA peaked at 2 hours before 
returning to baseline (Figure 4.2-A).  Interestingly, FXa did not increase EGR1 mRNA levels 
over the 6-hour time course.  2f-LIGRLO-amide, a PAR-2 specific agonist peptide, also  
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Figure 4.1.  FXa and thrombin activate p42/p44 MAPK signaling and ELK1 in 4T1 cells.  Confluent 
4T1 cells were stimulated with 125nM FXa, 20nM thrombin (FIIa), or 10% FBS+200nM PMA 
(FBS+PMA) for 5 minutes and blotted for pERK1/2 and total ERK1/2 (A), pELK1 and total ELK1 (B), or 
IκBα and GAPDH (C).  The pERK1/2 and pELK1 band intensities were quantified and normalized to the 
total ERK1/2 and total ELK1 band intensity, respectively.  Results are shown as mean ± SEM of four (A) or 
three (C) independent experiments. *P≤0.05 (treated versus SFM). The pELK1 blot is representative of two 
independent experiments. 
 73 
Figure 4.2.  EGR1 is expressed in 4T1 cells in response to thrombin.  Time course of EGR1 mRNA 
expression in 4T1 cells stimulated with 125nM FXa or 20nM thrombin (FIIa) (A), or 10µM PAR-2 agonist 
peptide (B).  mRNA levels at the indicated time points were measured by real time PCR.  Results are shown 
as mean ± SEM of three independent experiments (A).  P-values were calculated using a two-way ANOVA 
with a Bonferroni post-hoc analysis. ** P≤0.01 (FIIa versus control).  PAR-2 agonist peptide graph 
represents two independent experiments.  (C) 4T1 cells were incubated with 125nM FXa, 20nM thrombin 
(FIIa), or 10% FBS+200nM PMA (FBS+PMA) for 3 hours and blotted for EGR1 and GAPDH (left).  The 
pEGR1 band intensity was quantified and normalized to the GAPDH band intensity (right). Results are 
shown as mean ± SEM of three independent experiments. *P≤0.05. 
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increased EGR1 mRNA levels in 4T1 cells in a time-dependent manner (Figure 4.2-B).  In 
this experiment, EGR1 mRNA levels were highest at 3 hours.  EGR1 protein levels were also 
examined.  Western blot analysis of 4T1 whole cell lysates showed that thrombin induced 
EGR1 protein expression while FXa had no effect (Figure 4.2-C).   
 
Thrombin-induced PAI-1 expression in 4T1 cells requires the p42/p44 MAPK signaling 
pathway.   
Previous studies show that p42/p44 MAPK signaling positively regulates PAI-1 
expression in breast cancer cells and that the mouse PAI-1 promoter has at least one EGR1 
binding site30.  To demonstrate that the p42/p44 MAPK signaling pathway is necessary for 
thrombin-induced PAI-1 expression, the MEK inhibitor U0126 was used.  Treating 4T1 cells 
with U0126 before stimulation with FXa or thrombin reduced the levels of pERK1/2 (Figure 
4.3-A).  U0126 attenuated the induction of pELK1 in response to FXa or thrombin (Figure 
4.3-B).  Thrombin-induced EGR1 protein expression was also decreased in 4T1 cells pre-
treated with U0126 (Figure 4.3-C).  Surprisingly, U0126 did not decrease ELK1 
phosphorylation in 4T1 cells treated with FBS+PMA (Figure 4.3-B) but did decrease 
pERK1/2 and EGR1 protein levels in cells treated with the positive control (Figure 4.3-A and 
Figure 4.3-C).  Inhibition of the p42/p44 MAPK signaling pathway also significantly reduced 
PAI-1 accumulation in the culture supernatant of 4T1 cells incubated with thrombin for 24 
hours (Figure 4.3-D). 
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Figure 4.3.  U0126 attenuates MAPK signaling and PAI-1 expression in thrombin stimulated 4T1 
cells. Cells were pretreated with U0126 for 1 hour and then stimulated with 125nM FXa, 20nM thrombin 
(FIIa), or 10% FBS+200nM PMA (FBS+PMA) for 5 minutes.  Membranes were probed for pERK1/2 and 
total ERK1/2 (A), pELK1 and total ELK1 (B), or EGR1 and GAPDH (C). (D) PAI-1 levels in the cell 
culture supernatant was measured by ELISA.  Results are shown as mean ± SEM of four (A), three (C), 
and five (D) independent experiments. *P≤0.05 (DMSO versus 10µM U0126). The pELK1 blot is 
representative of two independent experiments. 
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DISCUSSION 
 The aim of this study was to determine the intracellular signaling pathways and 
transcription factors that regulate thrombin-induced PAI-1 gene expression in 4T1 cells. We 
examined the role of the NFκB and p42/p44 MAPK signaling pathways in thrombin-
mediated PAI-1 expression.  While there was no evidence of NFκB signaling, both FXa and 
thrombin increased the levels of pERK1/2 in 4T1 cells.  We have previously demonstrated 
that thrombin-cleaved PAR-1 transactivated PAR-2 to induce PAI-1 expression in 4T1 
cells14.  Reducing either PAR-1 or PAR-2 expression in 4T1 cells decreased the levels of 
pERK1/2 in response to thrombin (data not shown). The U0126 compound prevents activated  
MEK from phosphorylating ERK1/2.  U0126 inhibited phosphorylation of ERK1/2 and 
decreased PAI-1 protein levels. Taken together, the data indicate that thrombin activates 
PAR-1, which subsequently transactivates PAR-2, thereby inducing p42/p44 MAPK 
signaling.  
The transcription factor ELK1 is a downstream target of pERK1/2.  Phosphorylation 
of ELK1 increases its transcriptional activity by inducing a conformational change within the 
protein that allows for increased DNA binding activity and also by recruiting co-activators31.  
Both FXa and thrombin increased pELK1 levels in 4T1 cells. Interestingly, U0126 did not 
substantially decrease ELK1 phosphorylation in 4T1 cells treated with the positive control.  
This may reflect the fact that signaling pathways in addition to the p42/p44 MAPK pathway 
also induce ELK1 phosphorylation29,31. 
 pELK1 induces transcription of the immediate early gene EGR1 by binding to the 
serum response element (SRE) in the EGR1 promoter31,28.  Thrombin, but not FXa, increased 
EGR1 expression, indicating that FXa and thrombin activate different downstream signaling 
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pathways in 4T1 cells.  In chick fibroblasts, thrombin induced the phosphorylation of 
ELK128.  The subsequent transcriptional activity of pELK1 in these cells was dramatically 
increased by the p300 co-activator.  Furthermore, c-Jun N-terminal kinases (JNK) and p38 
MAPK induced ELK1 phosphorylation in NIH3T3 fibroblasts, which resulted in EGR1 
mRNA transcription29.  It is possible that thrombin activates multiple intracellular signaling 
pathways and transcription factors, including p42/p44 MAPK, ELK1, and p300 that increase 
EGR1 mRNA and protein expression in 4T1 cells.  Conversely, FXa activation of ERK1/2 
and ELK1 is not sufficient for EGR1 expression, potentially due to a lack of co-activator 
recruitment or activation of supplemental transcription factors. 
 Alternatively, EGR1 is negatively regulated by nerve growth factor induced-A 
(NGFI-A) binding proteins 1 and 2 (NAB1 and NAB2)32.  NAB1 is constitutively expressed 
whereas NAB2 is transiently expressed.  NAB2 expression is induced by similar signaling 
stimuli as EGR132.  The observed FXa-dependent signaling may result in the expression of 
both EGR1 and NAB2, thereby inhibiting EGR1 expression in 4T1 cells.  To fully 
understand the differential effects of FXa compared to thrombin, detailed studies of the 
EGR1 promoter region are necessary. 
 Using a PAR-2 agonist peptide, we show that PAR-2 activation increases EGR1 
mRNA expression in 4T1 cells.  Recently, a gene expression profile of PAR-1 and PAR-2 
dependent transcripts in human kidney cells was compiled, revealing that EGR1 is 
downstream of PAR-2 activation33.  This work independently validates our data. 
Furthermore, both FVIIa and FXa, presumably via PAR-2 activation, induced EGR1 mRNA 
expression34.  Together, we propose a model in which thrombin activates PAR-1, which then 
transactivates PAR-2 resulting in ERK1/2 phosphorylation and subsequent ELK1 
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phosphorylation.  In this model, pELK1 increases EGR1 gene transcription and protein 
expression thereby promoting PAI-1 expression (Figure 4.4).   
 In human breast cancer cells, ELK1 has been shown to bind the PAI-1 promoter 
directly, and upon epidermal growth factor (EGF) induced phosphorylation, promotes PAI-1 
transcription23.  Although ELK1 may indeed bind to the PAI-1 promoter, our data indicate 
that EGR1 induction is required for PAI-1 expression in the 4T1 mouse breast cancer cell 
line.  The signaling pathways activated by EGF versus thrombin may account for the 
different roles ELK1 plays in the transcriptional regulation of PAI-1.  Whether EGR1 serves 
as a crucial co-activator or as the major transcription factor regulating PAI-1 expression in 
4T1 cells has yet to be determined. 
Interestingly, preliminary data indicated that FXa activated ERK1/2 in the cells with 
reduced PAR-1 or PAR-2 expression, although some reduction in pERK1/2 levels was 
observed (data not shown).  In addition to PAR-1 and/or PAR-2, effector cell protease 
receptor-1 (EPR1) is transmembrane receptor that serves as a FXa receptor and is expressed 
on cancer cells35,36. The FXa-induced phosphorylation of ERK1/2 and ELK1 that was not 
mediated by activation of PAR-1 or PAR-2 may indeed be a result of EPR1 activation.  
However, there are no available antibodies or inhibitory peptides that will inhibit murine 
EPR1. 
In conclusion, PARs are cell surface receptors that, upon activation, mediate a variety 
of cellular effects.  The mechanism of receptor activation dictates the intracellular signaling 
pathway(s) that will be utilized.  The anti-fibrinolytic protein PAI-1 is expressed upon PAR-2 
activation of 4T1 cells.  Various signaling pathways regulate PAI-1 expression, many of 
which are induced by PAR-1 and PAR-2 activation.  In this study, we demonstrate that the  
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Figure 4.4.  The proposed signaling mechanism driving thrombin-induced PAI-1 expression.  (1) 
Thrombin activates PAR-1, which subsequently transactivates PAR-2.  (2) Activation of PAR-2 results in 
phosphorylation of ERK1/2. (3) pERK1/2 phosphorylates ELK1.  (4) pELK1 promotes EGR1 transcription.  
(5) EGR1 protein is translated.  (6) EGR1 protein induces PAI-1 transcription.  (7) PAI-1 is processed and 
released from the cells.  
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p42/p44 MAPK-ELK1-EGR1 pathway is required for thrombin-induced PAI-1 expression in 
metastatic murine breast cancer cells.  
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In the human breast cancer cell line MDA-MB-231, exogenously added FVIIa binds 
to TF and activates PAR-2.  This increases the migration and release of pro-angiogenic 
factors from the cells1,2.  The initial goal of my research project was to analyze TF-FVIIa-
PAR-2 signaling in non-metastatic (67NR) and metastatic (4T1) mouse breast tumor cell 
lines. 67NR cells only expressed PAR-1, while the 4T1 cells expressed both PAR-1 and 
PAR-2, making these cell lines appropriate models for this investigation.  However, in 
contrast to the literature using human breast cancer cells, mouse FVIIa did not activate the 
4T1 cells.  I concluded that the relatively low levels of TF and/or PAR-2 expressed in the 
4T1 cells did not sufficiently support TF-FVIIa-PAR-2 signaling.  From these results, I 
altered the direction of my project to explore roles of FXa and thrombin-induced signaling by 
PAR-1 and PAR-2 in breast tumor progression using the 4T1 murine mammary 
adenocarcinoma model. 
Activation of PAR-1 or PAR-2 induces the expression of uPA and PAI-1 in certain 
cancer cell lines1,3.  uPA and PAI-1 regulate the fibrinolytic pathway and also have roles in 
tumor invasion, angiogenesis, and metastasis4-7. I investigated whether FXa, which activates 
PAR-1 and PAR-2, or thrombin, which activates PAR-1, could increase either uPA or PAI-1 
expression in 4T1 cells in vitro.  Two novel findings were made.  First, FXa and thrombin 
activated PAR-1 resulting in a rapid release of stored uPA from inside the 4T1 cells.  Thus, 
activation of PAR-1 induces uPA secretion.  This observation was not specific to the 4T1 
cells as I obtained similar results using two other murine breast cancer cell lines (168FARN 
and 4T07) and a murine pancreatic cancer cell line (PAN02).  It would be interesting to 
further investigate if FXa and thrombin induce uPA secretion in non-transformed cells and to 
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determine if this PAR-1-dependent uPA secretory mechanism is applicable to human cell 
lines.  
The second novel finding was that thrombin-activated PAR-1 transactivated PAR-2 to 
induce PAI-1 mRNA and protein expression.  This is the first reported evidence that 
thrombin-induced PAI-1 is regulated by a PAR-1/PAR-2 complex.  A more detailed 
investigation of the PAR-1/PAR-2 complex was not feasible due to limited reagent 
availability for murine PAR-2.  For example, PAR-2 antibodies would have allowed me to 
determine if the PAR-1/PAR-2 complex was localized to lipid rafts or caveolae.  The PAR-1 
agonist peptide SFLLRNP-NH2, corresponding to the tethered ligand sequence of human 
PAR-1, activates both human and murine PAR-2 in vitro8.  Lack of anti-mouse PAR-2 
antibodies directed towards the activation loop of the receptor prevented me from examining 
if the tethered ligand of thrombin-activated PAR-1 interacts with the activation loop of PAR-
2.  Furthermore, the transmembrane domain 4 of PAR-4 appears to interact with PAR-1 to 
form a PAR-1/PAR-4 complex (Dr. Marvin Nieman, personal communication).  A similar 
interaction may occur in between PAR-1 and PAR-2 in 4T1 cells.  To perform these 
experiments, antibodies against multiple mouse PAR-1 and mouse PAR-2 epitopes would 
need to be raised and mutated receptors would need to be generated.    
To determine if activation of the PAR-1/PAR-2 complex was unique to thrombin, I 
incubated 4T1GFP, 4T1ΔPAR-1, and 4T1ΔPAR-2 cells with plasmin.  Similar to thrombin, 
plasmin-induced uPA was PAR-1 dependent whereas PAI-1 induction required both PAR-1 
and PAR-2 expression (Figure 5.1-A and B).  These results reinforce my hypothesis stated in 
Chapter 3 that only non-membrane bound proteases, such as thrombin and plasmin, are 
capable of activating the PAR-1/PAR-2 complex, whereas membrane bound proteases, like  
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Figure 5.1.  Plasmin induces uPA and PAI-1 in 4T1 cells.  uPA protein (A) and PAI-1 protein (B) were 
measured by ELISA after 24 hour incubation with 100nM plasmin. Results are shown as mean ± SEM of 
three independent experiments. *P≤0.05. 
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FXa, are not.  Additional experiments using membrane-bound proteases such as APC bound 
to endothelial protein C receptor (EPCR) or matriptase may be able to further confirm this 
hypothesis. 
The signaling mechanism regulating thrombin-induced PAI-1 expression in 4T1 cells 
was also explored.  I found that thrombin activates the ERK1/2-ELK1-EGR1 pathway and 
that the p42/p44 MAPK pathway is required for PAI-1 expression.  Surprisingly, FXa 
increased the phosphorylation of ERK1/2 and ELK1 in 4T1GFP, 4T1ΔPAR-1, and 4T1ΔPAR-2 
cells but FXa did not induce either EGR1 mRNA or protein expression.  I propose that 
thrombin signaling was sufficient to recruit the necessary transcriptional co-factors for EGR1 
expression while FXa was not.  This may explain why thrombin, but not FXa, is capable of 
inducing PAI-1 expression in 4T1 cells.  To further explore this possibility and to determine 
if EGR1 is the sole transcription factor needed for thrombin-induced PAI-1 expression in 
4T1 cells, EGR1 would need to be silenced and PAI-1 promoter studies would have to be 
conducted.     
Based on the literature and my in vitro data using 4T1 cells, I propose a model in 
which activation of PAR-1 induces the release of uPA, thus promoting sustained ECM 
proteolysis (Figure 5.2-A) as PAR-1 localized at the leading edge of invasive cancer cells9. 
Activation of PAR-1 by proteases, such as FXa or thrombin, results in the rapid release of 
uPA from 4T1 cells.  uPA converts plasminogen to plasmin which then activates MMP-110. 
Plasmin and MMP-1 activate PAR-1 thereby creating a positive feedback loop11,12. 
Additionally, plasmin and MMP-1 degrade the ECM, freeing and activating cell- or matrix-
bound growth factors in the process13. The constant presence of these proteases and the 
kinetics of uPA secretion favors persistent ECM degradation and growth factor availability.  
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A 
B 
Figure 5.2.  Proposed mechanism of how coagulation protease-mediated activation of PAR-1 or the 
PAR-1/PAR-2 complex promotes tumor invasion.  (A) FXa or thrombin activates PAR-1, inducing the 
rapid release of stored uPA from 4T1 cells.  uPA converts plasminogen (Plg) to plasmin (Pm) on the cell 
surface.  Plasmin activates pro-MMP-1 to active MMP-1.  Both plasmin and MMP-1 degrade the 
extracellular matrix and activate PAR-1 to release more uPA, creating a positive feedback loop. (B) 
Activation of the PAR-1/PAR-2 complex by thrombin increases PAI-1 expression.  PAI-1 competes with 
uPAR for vitronectin binding and disrupts the uPA-uPAR complex binding to integrins (purple) by binding 
to uPA and internalizing the PAI-uPA-uPAR complex, thereby favoring cellular de-adhesion. 
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Activation of the PAR-1/PAR-2 complex also results in PAI-1 mRNA and protein 
expression.  PAI-1 promotes cellular de-adhesion by competing with urokinase plasminogen 
activator receptor (uPAR) for vitronectin binding and by disrupting uPA-uPAR-integrin 
complexes via internalization of PAI-1-uPA-uPAR complexes (Figure 5.2-B)14.  Rapid ECM 
degradation mediated by uPA activity, followed by PAI-1 induced cellular de-adhesion may 
further promote or sustain tumor cell invasion. 
The data obtained from the in vivo experiments revealed that PAR-1 has a role in the 
growth of 4T1 cells and that PAR-2 is involved in hematogenous metastasis in the 4T1 breast 
tumor model.  The mechanisms underlying these results were not delineated.  There were no 
significant differences in uPA or PAI-1 levels between plasma samples from mice implanted 
with 4T1GFP, 4T1ΔPAR-1, or 4T1ΔPAR-2 cells.  Lower levels of uPA were detected in the plasma 
samples from tumor bearing mice in comparison to control mice while the opposite was true 
for PAI-1.  A possible explanation for the decreased uPA levels in tumor bearing mice is that 
the majority of uPA was bound to the surface of the 4T1 cells and subsequently internalized 
as part of the PAI-1-uPA-uPAR complex.  Laser capture microdissection of 4T1GFP, 4T1ΔPAR-
1, or 4T1ΔPAR-2 tumor cells followed real-time PCR could be used to determine if reducing 
PAR-1 or PAR-2 expression in 4T1 cells has an effect on PAI-1 expression in these cells in 
vivo.  This approach might not be useful in detecting changes in uPA expression as my in 
vitro data indicates that activating PAR-1 or PAR-2 does not regulate uPA transcription.  An 
alternative approach is to grow 4T1GFP, 4T1ΔPAR-1, and 4T1ΔPAR-2 tumors in either uPA or 
PAI-1 deficient animals and determine uPA and PAI-1 protein levels in the plasma and in 
stained tumor sections.   
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Activation of PAR-1 or PAR-2 mediates inflammation1,15.  I investigated the effects 
of reducing PAR-1 or PAR-2 expression in tumor cells on in vivo cytokine levels.  
Surprisingly, of the 62 cytokines assayed, reducing PAR-1 or PAR-2 expression significantly 
impacted the expression of only one cytokine, granulocyte colony stimulating factor (GCSF). 
Tumor-derived GCSF recruits tumor associated neutrophils (TANs), myeloid suppressor 
cells, and endothelial progenitor cells, thereby promoting angiogenesis, invasion, and 
immunosuppression16-20.  In vivo, plasma GCSF levels were significantly reduced in the 
samples from mice with 4T1ΔPAR-2 tumors compared to mice with 4T1GFP or 4T1ΔPAR-1 
tumors.  Low levels of GCSF were detected in the plasma of control mice.  In vitro, 
activation of PAR-1 or PAR-2 increased GCSF in the culture supernatant of 4T1 cells. 
Staining tumor sections for vascular density, neutrophils, and CD11b+/GR1+ myeloid 
suppressor cells may yield useful information in further characterizing the role of PAR-2-
dependent GCSF expression in the 4T1 breast tumor model.  Additionally, reducing PAR-2 
expression in 4T1 cells decreased both lung metastasis and GCSF levels in vivo.  Using a 
neutralizing antibody against GCSF in vivo could help determine if GCSF is involved in the 
hematogenous metastasis of 4T1 cells. 
TF and the downstream coagulation proteases contribute to malignancy21.  PARs are 
the cellular substrates for FVIIa, FXa, and thrombin.  Inhibition of TF could reduce PAR 
activation by FVIIa, FXa, or thrombin.  Inhibition of FVIIa, FXa, or thrombin has shown 
some promise in experimental models of melanoma, colorectal cancer, and glioblastoma 22-24. 
However, targeting TF, FVIIa, FXa, or thrombin may have undesired hemorrhagic 
consequences.    Despite these findings, there are numerous proteases present in the tumor 
stroma that could activate PAR-1 and PAR-2 in the absence of TF and coagulation proteases.  
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Targeting PAR-1 and/or PAR-2 seems promising; however, these receptors regulate 
overlapping sets of genes1,25. Using the 4T1GFP, 4T1ΔPAR-1, and 4T1ΔPAR-2 cell lines to create 
expression profiles of genes induced by the activation of PAR-1, PAR-2, or by PAR-1 
transactivation of PAR-2 would elucidate the potential druggability of these receptors.  
Creating such comprehensive gene expression profiles will require the use of a variety of 
PAR-1 and PAR-2 agonists. Nevertheless, specifically targeting tumor PAR-1 and/or PAR-2 
may be difficult since both are ubiquitously expressed. 
The goal of my project was to examine if coagulation protease activation of PAR-1 or 
PAR-2 expressed by 4T1 breast cancer cells modulates the expression of components of the 
plasminogen activator system.  The data presented here is not an exhaustive investigation of 
the entire plasminogen activator system as I focused specifically on uPA and PAI-1.  uPAR 
and tissue plasminogen activator (tPA) also have roles in promoting the malignant phenotype 
of cancer cells26-28.  It would be interesting to examine if activation of PAR-1 and/or PAR-2 
regulates uPAR or tPA expression in the 4T1 cells and the effects this may have on breast 
tumor progression. 
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APPENDIX I: 
Effect of Reducing Protease-Activated Receptor-1 or -2 Expression in Breast Tumor 
Cells on Tumor Growth, Metastasis, and Cytokine Production In Vivo 
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INTRODUCTION 
Protease activated receptor-1 (PAR-1) and PAR-2, members of the G-protein coupled 
receptor family, have been implicated in promoting tumor growth, survival, angiogenesis, 
and invasion1-3.  PAR-1 is activated by the coagulation proteases FVIIa, FXa and thrombin, 
in addition to matrix metalloproteinase-1 (MMP-1), plasmin, and activated protein C (APC)4-
8.  PAR-2 is also activated by coagulation proteases, namely FVIIa and FXa9.  Other PAR-2 
agonists include trypsin, matriptase, and mast cell tryptase10.  We have published that PAR-1 
and PAR-2 positively regulate the expression of urokinase plasminogen activator (uPA) and 
its inhibitor, plasminogen activator inhibitor-1 (PAI-1)11.  Inflammatory cytokines are also 
expressed in response PAR-1 or PAR-2 activation12,13.  The goal of this study was to 
determine the effects of reducing tumor cell PAR expression on tumor growth and metastasis 
as well as the impact on uPA, PAI-1, and inflammatory cytokine levels in vivo.   
 
MATERIALS AND METHODS 
Reagents.    
Sterile syringes and needles were obtained from BD Biosciences. Sodium dodecyl 
sulfate (SDS), glycerol, tris(hydroxymethyl)aminomethane (Tris), phosphate buffered saline 
(PBS), trypan blue, penicillin/streptomycin, and sodium citrate were purchased from Sigma-
Aldrich.  Complete protease inhibitor cocktail tablets and phosphatase inhibitors were 
obtained from Roche. Buffered 10% formalin pH 6.8-7.2 was purchased from VWR.  
Bouin’s fixative was purchased from Ricca Chemical Company.  PAR-1 and PAR-2 agonist 
peptides were obtained from Calbiochem.  Purified human coagulation proteases factor Xa 
(FXa) and alpha-thrombin (FIIa) were purchased from Haematologic Technologies Inc.  
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Recombinant mouse factor VIIa (mFVIIa) was provided by Dr. Lars Petersen (Novo 
Nordisk). 
 
Animals.   
All animal experiments were performed in accordance with the guidelines of the 
institutional animal care and use committee (IACUC) at the University of North Carolina at 
Chapel Hill (UNC-CH).  6-8 week old female Balb/c mice were obtained from Charles River 
Laboratories.  The mice were housed and maintained by the Division of Laboratory Animal 
Medicine (UNC-CH).  Mice were housed in 12-hour day/night cycles. 
 
Cell culture.   
The highly metastatic 4T1 murine mammary adenocarcinoma cell line was obtained 
from Dr Fred Miller (Michigan Cancer Foundation).  4T1GFP, 4T1ΔPAR-1, and 4T1ΔPAR-2 cell 
lines were generated as previously described11.  Cells lines were maintained in minimal 
essential media (MEM)-alpha (Gibco) supplemented with 10% fetal bovine serum (Omega 
Scientific), and 1% penicillin/streptomycin.  Prior to implantation, cells were detached from 
the flasks with Versene (UNC-CH Tissue Culture Facility) and a sub-sampling was tested for 
viability by trypan blue exclusion.  
 
In vivo tumor studies.  
Tumor implantation. Animal procedures were performed using sterile conditions by 
the Animal Studies Core Facility (UNC-CH).  The recipient mice were anesthetized and a 
small midline incision was made in the lower abdomen and then angled toward the left 
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inguinal mammary fat pad.   Using a sterile syringe with a 27-guage needle, 100µL of a 
single cell suspension in PBS was injected into the 4th mammary fat pad.  Sterile PBS was 
injected into the control mice.  The incision was closed with wound clips.  Once fully healed, 
the wound clips were removed.   
Tumor growth rates and weight.  To determine the growth rate of 4T1GFP, 4T1ΔPAR-1, 
or 4T1ΔPAR-2 tumors, 50,000 cells were implanted into the 4th mammary fat pad.  Tumor 
growth was monitored for 22 days by taking digital caliper measurements of the length and 
width of each tumor.  The tumor volume was calculated using the following equation: 
Volume (cm3) = ½ Length x Width2.  At the conclusion of the experiment, the tumors were 
carefully excised, rinsed in ice cold PBS, and weighed. 
Quantification of spontaneous pulmonary metastasis.  For all spontaneous metastasis 
experiments, 100,000 4T1GFP, 4T1ΔPAR-1, or 4T1ΔPAR-2 cells were implanted into the 4th 
mammary fat pad and allowed to grow for 21 days.  At the conclusion of the experiment, the 
lungs were removed and placed in Bouin’s fixative.  The surface metastatic nodules on the 
lungs were counted. 
 
Exsanguination and plasma preparation.   
At the time of sacrifice, the animals were anesthetized and exsanguinated via the 
inferior vena cava.  500µL of blood was drawn into a sterile syringe containing 50µL of 
sodium citrate as an anticoagulant.  The blood was placed on ice then centrifuged at 4,000 x 
g for 15 minutes at 4oC.  The plasma was stored at -80oC until use. 
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uPA and PAI-1 enzyme-linked immunosorbent assays.   
Confluent 4T1 cell monolayers were serum starved for 16 hours in serum free media 
(SFM) composed of MEM-alpha (Gibco) supplemented with 1% penicillin/streptomycin.  
Following starvation, fresh SFM containing either PAR-1 agonist peptide, PAR-2 agonist 
peptide, mFVIIa, FXa, or thrombin were added to the wells.  The cell culture supernatant was 
collected after 24 hours, centrifuged at 5,000 x g for 5 minutes at 4oC to remove cellular 
debris, and frozen at -20oC.  An enzyme-linked immunosorbent assay (ELISA) was used to 
determine the levels of uPA, PAI-1, (Molecular Innovations) and granulocyte colony-
stimulating factor (GCSF; R&D Systems) in the plasma samples and cell culture 
supernatants.   
 
Cytokine array.   
Plasma samples from control mice, 4T1GFP, 4T1ΔPAR-1, or 4T1ΔPAR-2 tumor bearing 
mice were pooled according to their respective cohorts.  Each pooled plasma sample was 
added to an individual well of the RayBio Mouse Cytokine Antibody Array G Series 3 
(RayBiotech) and the experiment was performed as per the manufacturers protocol with 
minor alterations.  A 1:2,000 dilution of IRDye 680 Streptavidin (LI-COR Biosciences) was 
used for detection and the slides were scanned and quantified using the Odyssey Infrared 
Imaging System (LI-COR Biosciences). 
 
Statistics.   
 GraphPad Prism 4 for Mac (GraphPad Software) was used to perform statistical 
analyses.  All data are presented as means ± standard error of the mean (SEM). Data sets 
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were analyzed using a two-tailed students t-test.  Alternatively, a two-way analysis of 
variance (ANOVA) with a Bonferroni post-hoc analysis was utilized when indicated. 
Grubb’s test was performed to determine statistical outliers.  P≤0.05 was considered 
statistically significant.   
 
RESULTS AND DISCUSSION 
Decreasing PAR-1 expression in 4T1 cells reduces breast tumor growth.   
To determine if PAR-1 or PAR-2 expression contributes to growth of 4T1 tumors, 
4T1GFP, 4T1ΔPAR-1, or 4T1ΔPAR-2 cells were implanted into the mammary fat pad of 
immunocompetent female Balb/c mice.  The growth rate and final weight of 4T1ΔPAR-1 
tumors was decreased by roughly 40% in comparison to that of 4T1GFP and 4T1ΔPAR-2 tumors 
(Figure A.1).  These data are consistent with the literature which suggests that thrombin, a 
PAR-1 agonist, functions as a tumor growth factor14.  Additionally, dabigatran, a direct 
thrombin inhibitor, reduced the growth of 4T1 cells both in vitro and in vivo, presumably by 
reducing the activation of PAR-115.  Decreasing PAR-2 expression in 4T1 cells did not effect 
tumor growth (Figure A1.1).  Together, the data suggest that PAR-1 activation promotes the 
growth of 4T1 breast tumor cells in vivo. 
 
Decreasing PAR-2 expression in 4T1 cells reduces hematogenous metastasis.   
4T1 cells spontaneously metastasize from the mammary fat pad to distant sites 
including the lymph nodes, lung, liver, bone, and brain16,17.  Silencing either PAR-1 or PAR-
2 expression in 4T1 cells reduced the extent to which the cells hematogenously metastasized 
to the lungs (Figure A1.2).  The lungs of mice implanted with 4T1ΔPAR-1 or 4T1ΔPAR-2 tumors  
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Figure A1.1.  Silencing PAR-1 decreased tumor growth in vivo.  (A) Tumor growth rate of 4T1GFP, 
4T1ΔPAR-1, or 4T1ΔPAR-2 tumors.  Mice were implanted with 50,000 4T1GFP (n=5 mice), 4T1ΔPAR-1 (n=7 
mice), or 4T1ΔPAR-2 (n=5 mice) into the 4th mammary fat pad.  Digital caliper measurements were recorded 
and used to calculate the tumor volume using the following ellipsoid equation: Volume (cm3) = ½ Length 
x Width2.  Error bars represent the SEM.  P-values were calculated using a two-way ANOVA with a 
Bonferroni post-hoc analysis.  * P≤0.05 and ** P≤0.001 (4T1GFP versus 4T1ΔPAR-1), ## P≤0.001 (4T1ΔPAR-2 
versus 4T1ΔPAR-1).  (B) Tumor weight at time of sacrifice.  4T1GFP (n=5), 4T1ΔPAR-1 (n=7), and 4T1ΔPAR-2 
(n=5) tumors were excised and weighed. .  Error bars represent the SEM.  P-values were calculated using 
a two-tailed students t-test.  * P≤0.05 (4T1GFP versus 4T1ΔPAR-1), ## P≤0.001 (4T1ΔPAR-2 versus 4T1ΔPAR-1). 
 103 
Figure A1.2.  Reducing PAR-2 expression in tumor cells decreases spontaneous lung metastasis. 
Mice were implanted with 100,000 4T1GFP (n=6 mice), 4T1ΔPAR-1 (n=5 mice), or 4T1ΔPAR-2 (n=6 mice) into 
the 4th mammary fat pad.  At the time of sacrifice, the lungs from each mouse were excised, rinsed in 
PBS, and fixed in Bouin’s fixative.  The visible metastatic nodules on the surface of each lung were 
counted in duplicate and averaged. Error bars represent the SEM.  * P≤0.05 (4T1GFP versus 4T1ΔPAR-2).  
One statistically significant outlier per tumor cohort was excluded using Grubb’s test with a P-value of 
P≤0.05. 
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had fewer metastatic foci when compared to the lungs of mice with 4T1GFP tumors.  
However, only the 4T1ΔPAR-2 tumors displayed a statistically significant reduction in 
metastasis.  This data suggests that PAR-2 contributes to tumor metastasis in the 4T1 breast 
tumor model.  In vitro, activation of PAR-1 and PAR-2 regulate the expression of 
overlapping sets of genes12,13.  This may also be true in 4T1 cells in vivo.  An attempt to 
silence both PAR-1 and PAR-2 in the same cell was unsuccessful (data not shown). 
 
Reducing PAR-1 or PAR-2 expression in 4T1 cells does not alter plasma uPA or PAI-1 
levels.   
To examine if reducing tumor cell PAR-1 or PAR-2 expression affects uPA or PAI-1 
levels in vivo, plasma from control mice, 4T1GFP, 4T1ΔPAR-1, or 4T1ΔPAR-2 tumor bearing mice 
was analyzed by ELISA.  Similar levels of uPA were detected in the plasma of mice 
implanted with 4T1GFP, 4T1ΔPAR-1, or 4T1ΔPAR-2 tumors (Figure A1.3-A).  Interestingly, 
significantly more circulating uPA was present in the plasma from control (no tumor) mice in 
comparison to that of tumor bearing mice.  Plasma PAI-1 levels were increased in tumor 
bearing mice in comparison to plasma from the control (no tumor) mice (Figure A1.3-B).  
However, there were no significant differences in the plasma PAI-1 levels between the 
cohorts of tumor bearing mice.   
Our results suggest that reducing the expression of PAR-1 or PAR-2 in 4T1 cells does 
not impact the plasma levels of uPA or PAI-1 in tumor bearing mice.   There are a variety of 
cell types that comprise breast tumors, including fibroblasts, endothelial cells, adipocytes, 
macrophages, and neutrophils.  All of these cell types are known to express uPA and PAI-118-
21.  This experiment did not specifically examine the cellular source of uPA and PAI-1.   
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Figure A1.3.  Determination of uPA and PAI-1 levels in vivo.  Quantification of plasma levels of uPA (A) 
and PAI-1 (B) by ELISA.  Plasma samples were taken from control mice (n=4), 4T1GFP (n=7), 4T1ΔPAR-1 
(n=6), and 4T1ΔPAR-2 (n=7).  Error bars represent the SEM.  * P≤0.05, ns (not significant).   
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Therefore, a different approach is needed to truly determine the effects of tumor cell PAR-1 
and PAR-2 expression on uPA and PAI-1 in vivo.  For example, implanting the 4T1GFP, 
4T1ΔPAR-1, and 4T1ΔPAR-2 cells into uPA or PAI-1 deficient mice. 
 
Reducing PAR-2 expression in 4T1 cells decreases GCSF levels in vivo and in vitro.  
To examine if PAR-1 or PAR-2 activation contributes to inflammatory cytokine 
production, pooled plasma from each cohort of mice was assayed for 62 different cytokines 
using a cytokine antibody array.  Reducing either PAR-1 or PAR-2 expression in the tumor 
cells resulted in decreased plasma levels of GCSF, granulocyte macrophage colony-
stimulating factor (GM-CSF), chemokine (C-X-C motif) ligand-16 (CXCL-16), and 
interleukin-12 in comparison to plasma from mice with 4T1GFP tumors (Figure A1.4-A).  
GCSF was further investigated due to its robust signal intensity and the recent reports that 
this chemokine promotes tumor aggressiveness22-24.  
To confirm the cytokine array data, plasma GCSF levels were measured by ELISA. 
Plasma levels of GCSF from each cohort of tumor bearing mice were significantly elevated 
in comparison to control mice (Figure A1.4-B).  Within the tumor cohort, a reduction in 
GCSF was observed in the plasma of mice implanted with 4T1ΔPAR-2 tumors compared with 
mice implanted with 4T1GFP or 4T1ΔPAR-1 tumors.  This data suggest that expression of PAR-
2 on tumor cells plays a role in the in vivo production of GCSF in the 4T1 breast cancer 
model. 
To extend these observations, 4T1 cells were stimulated with increasing 
concentrations of PAR-1 or PAR-2 specific agonist peptides in vitro.  While both PAR-1 and 
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Figure A1.4.  Silencing PAR-2 expression alters cytokine production in vivo.  (A) The cytokine profile 
was generated using pooled plasma from each respective cohort of mice.  Cytokine antibodies were 
spotted in duplicate on the slide.  Error bars represent the SEM of duplicate antibody spots. (B) An ELISA 
was used to determine the levels of GCSF in the individual plasma samples. Control mice (n=4), 4T1GFP 
(n=7), 4T1ΔPAR-1 (n=6), and 4T1ΔPAR-2 (n=7).  Error bars represent the SEM. * P≤0.05. 
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PAR-2 agonist peptides increased the amount of GCSF in the culture supernatant of 4T1 
cells, a stronger induction was observed with the PAR-2 agonist peptide (Figure A1.5-A).  It 
has been demonstrated that agonist peptide activation of PARs results in different cellular 
responses compared with proteolytic activation10.  Aware of this, 4T1 cells were stimulated 
with FVIIa, FXa, or thrombin (FIIa).  Incubating 4T1 cells with mFVIIa did not induce 
GCSF in vitro (data not shown).  FXa modestly increased the amount of GCSF in the culture 
supernatant while thrombin resulted in a more pronounced accumulation of GCSF (Figure 
A.5-B).  Incubating 4T1GFP, 4T1ΔPAR-1, and 4T1ΔPAR-2 cells with FXa or thrombin revealed 
that these coagulation proteases activate PAR-1 to induce GCSF (Figure A.6).  This data 
does not exclude PAR-2 from inducing GCSF in vitro because all of the PAR-2 proteolytic 
agonists were not examined in vitro.  In addition to FVIIa and FXa, PAR-2 is activated by, 
mast cell tryptase, kallikreins, and matriptase, all of which are present in the tumor 
microenvironment25-28.  
We found a new relationship between PAR activation and GCSF expression.  GCSF 
is a granulocyte chemoattractant.  Of the granulocyte lineage, neutrophils have recently been 
implicated in tumor progression.  Tumor associated neutrophils (TANs) are thought to 
contribute to tumor progression by favoring angiogenesis and releasing extracellular matrix 
degrading proteases29,30.  Furthermore, GCSF also recruits endothelial progenitor cells and 
pro-angiogenic myeloid-derived suppressor cells22,23. This report provides preliminary data 
that merit further exploration into the role of PAR-induced GCSF and its effects on tumor 
growth and metastasis.  
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Figure A1.5.  Activation of PAR-1 and PAR-2 induces GCSF in vitro.   4T1 cells were grown to 
confluence and starved in serum free media (SFM) for 16 hours before being stimulated with PAR-1 or 
PAR-2 agonist peptides (A) or 125nM FXa or 20nM thrombin (B) for 24 hours.  GCSF levels in the cell 
culture supernatants were measured by ELISA. Results are shown as mean ± SEM of at least three 
independent experiments. *P≤0.05. 
 
 110 
Figure A1.6.  Thrombin increases GCSF expression in a PAR-1-dependent manner.  Confluent 
4T1GFP, 4T1ΔPAR-1, and 4T1ΔPAR-2 cells were starved for 16 hours then treated with 125nM FXa or 20nM 
thrombin (FIIa) for an additional 24 hours.  GCSF levels in the culture supernatant were measured by 
ELISA. Results are shown as mean ± SEM of at least three independent experiments. *P≤0.05. 
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 More than a century ago, Armand Trousseau first described an association between 
cancer and the coagulation system1,2. Later it was discovered that tumor cells release 
procoagulant microvesicles (often referred to as microparticles) into the culture medium that 
may be responsible for activation of the coagulation system3. The procoagulant protein tissue 
factor (TF) is expressed by a variety of tumors. Importantly, levels of TF expression increase 
with advanced cancer stage and high levels are associated with an increased mortality4–7. In 
glioblastoma cells, TF expression is induced by hypoxia and activation of the epidermal 
growth factor receptor8,9. One reason for the increased mortality may be that cancer patients 
have a high rate of venous thromboembolism. For instance, 11.1% of brain cancer patients 
have a thrombotic event within 1 year of diagnosis10. Indeed, tumor cells release TF-positive 
microparticles into the blood in mouse models and in cancer patients, and these 
microparticles may be responsible for triggering venous thrombosis11–14. Activation of 
coagulation by tumor cell TF also enhances pulmonary metastasis in a fibrin-dependent 
manner15,16. Finally, tumor cell TF enhances tumor growth and angiogenesis6,17. An earlier 
study found that overexpression of TF in Meth-A sarcoma cells increased tumor growth and 
angiogenesis in mice18. More recently, Rak and colleagues19 showed that a selective decrease 
in TF expression reduced the growth of human colorectal cancer cells and angiogenesis in 
severe combined immunodeficiency mice. 
 Ixolaris is a tick salivary protein that has two Kunitz-like domains that are similar to 
the Kunitz domains found in tissue factor pathway inhibitor. In this issue of the Journal of 
Thrombosis and Haemostasis, Carneiro-Lobo et al.20 demonstrate that inhibition of the TF–
factor (F)VIIa complex with Ixolaris decreases the growth of human glioblastoma tumors 
(U87-MG) in nude mice without increasing bleeding20. Moreover, the inhibitor reduced 
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vascular endothelial growth factor (VEGF) expression and angiogenesis. There are two 
limitations of the study. First, U87-MG cells were injected subcutaneously rather than 
intracranially. Orthotopic xenografts are more physiological models of tumorigenesis, and in 
the case of gliomas it is unlikely that systemic administration of Ixolaris would gain access to 
the brain. Second, Ixolaris inhibits both the TF–FVIIa complex and activation of FX by the 
intrinsic tenase complex. Therefore, it is unclear if the effects of Ixolaris are as a result of 
inhibition of the TF–FVIIa complex and/or a reduction in levels of the downstream 
coagulation proteases FXa and thrombin (Figure A2.1). 
 Most of the in vitro studies on TF–FVIIa signaling have been performed using a human 
keratinocyte cell line and MDA-MB-231 human breast cancer cells21,22. In MDA-MB-231 
cells, the TF–FVIIa complex activates protease-activated receptor-2 (PAR-2) and induces the 
expression of several pro-angiogenic mediators, such as VEGF, interleukin-8 (IL-8) and 
chemokine (C-X-C motif) ligand 1 (CXCL1)22–24. This led to the notion that TF expression 
by tumor cells enhances tumor growth in vivo by activation of PAR-2 (Figure A2.1). As 
noted by Carneiro-Lobo et al.20, MDA-MB-231 cells express very high levels of TF in 
comparison to U87-MG glioblastoma cells. We analyzed TF expression in an array 
database25 and found that MDA-MB-231 cells express much higher levels of TF than 99 
different primary breast tumor samples of varying stages and grades (T. McEachron, F. 
Church, N. Mackman, unpublished data). The results indicate that MDA-MB-231 cells may 
not be the best breast tumor model for studying TF-related signaling events. 
 The hypothesis that tumor cell TF enhances tumor growth in vivo has been tested in a 
variety of mouse models. One study showed that inhibition of the TF–FVIIa complex with 
NAPc2, a nematode anticoagulant protein, decreased tumor growth and angiogenesis of B16 
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Figure A2.1. Contribution of tissue factor (TF), coagulation proteases and protease-activated 
receptors (PARs) to tumor angiogenesis. Formation of the TF–factor (F)VIIa complex on the surface 
of tumor cells activates the coagulation system. Cleavage of PAR-2 by FVIIa or FXa induces the 
expression of various pro-angiogenic proteins, including vascular endothelial growth factor (VEGF), 
interleukin-8 (IL-8) and matrix metalloproteinases (MMPs). Activation of PAR-1 by thrombin or FXa 
induces a similar set of genes. Various anticoagulants target different proteases of the coagulation 
cascade, such as direct thrombin inhibitors (DTIs). 
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melanoma cells and Lewis lung carcinoma cells26. NAPc2 also inhibited the growth of 
colorectal tumors in mice27. In contrast, specific inhibition of FXa using the nematode 
anticoagulant protein NAP5 did not reduce tumor growth26. In other studies, a humanized 
anti-TF antibody called CNTO859 inhibited growth of MDA-MB-231 tumors and human 
epithelial tumors in immunodeficient mice9,28. These studies demonstrate that inhibition of 
TF reduces tumor growth in a variety of mouse models. 
 Other studies have focused on the mechanism by which TF contributes to tumor 
growth. Importantly, a monoclonal antibody called 10H10, which inhibits TF–FVIIa 
signaling without affecting its procoagulant activity, reduced tumor growth and angiogenesis 
of both MDA- MB-231 and melanoma (m24Met cells)29. Moreover, inhibition of PAR-2 but 
not PAR-1 decreased the growth of the MDA-MB-231 xenografts29. Finally, in a genetically 
engineered mouse model of adenocarcinoma, tumors developed more slowly in PAR-2−/− 
mice compared with tumors in either wild-type mice or PAR-1−/− mice30. However, tumors 
isolated from PAR-2−/− mice exhibited the same growth rate in wild-type mice as those 
isolated from control mice30. Although these studies support a role of TF and PAR-2 in tumor 
growth in different mouse models, further studies are required to determine if the TF–FVIIa–
PAR-2 signaling pathway is necessary for the growth of a wide variety of tumor types. 
 The paper by Carneiro-Lobo used a human glioblastoma tumor cell line20. Importantly, 
several studies have shown that thrombin plays a prominent role in the growth of gliomas by 
increasing VEGF expression in both human and rat glioma cell lines31,32. In addition, 
intracerebral infusion of argatroban, a specific thrombin inhibitor, reduced tumor growth in a 
C6 glioma model33. These results indicate that thrombin, possibly via PAR-1 signaling, plays 
a role in the growth of gliomas in vivo (Figure A2.1). 
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 It is somewhat surprising that there are few reports of bleeding in studies using 
anticoagulants to treat tumor-bearing mice. The one exception is that specific inhibition of 
FXa using the anticoagulant protein NAP5 resulted in high mortality rates as a result of 
intraperitoneal hemhorrage26. One possibility is that tumor-bearing mice are hyper-
coagulable because of the presence of TF-positive microparticles in the blood11,12,19 (J.-G. 
Wang, T. McEachron, N. Mackman, unpublished data). These procoagulant microparticles 
may prevent hemorrhage in anticoagulated mice and explain the low incidence of bleeding in 
these studies. 
Inhibiting the TF–FVIIa complex is a potential therapeutic approach to treat multiple 
solid tumor types. Additional benefits of this approach would be a reduction in metastasis 
and thrombosis. However, the greatest challenge to targeting TF is to find an efficacious dose 
of inhibitor that does not cause bleeding in cancer patients. 
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